| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abstracts Index
|
|
|
2005
|
8 |
3 |
p. 426-432
7 p.
|
artikel
|
| 2 |
CN4 EXPLICIT VALUATION OF PASS-THROUGH TECHNOLOGIES UNDER MEDICARE: IS IT FEASIBLE OR DESIRABLE]
|
Mohr, P
|
|
2005
|
8 |
3 |
p. 239-
1 p.
|
artikel
|
| 3 |
CNI COST-EFFECTIVENESS OF ONCE WEEKLY EPOETIN ALFA AND DARBEPOETIN ALFA IN TREATING CHEMOTHERAPY-INDUCED ANEMIA
|
Ben-Hamadi, R
|
|
2005
|
8 |
3 |
p. 238-
1 p.
|
artikel
|
| 4 |
CN3 ONCOLOGISTS' COST-EFFECTIVENESS THRESHOLDS FOR NEW CANCERTHERAPIES
|
Nadler, E
|
|
2005
|
8 |
3 |
p. 239-
1 p.
|
artikel
|
| 5 |
CN2 VALUE-FOR-MONEY OF PEMETREXED PLUS CISPLATIN VERSUS CISPLATIN ALONE IN THE TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA
|
Davey, P
|
|
2005
|
8 |
3 |
p. 238-239
2 p.
|
artikel
|
| 6 |
Cost-Effectiveness of Face-to-Face Smoking Cessation Interventions: A Dynamic Modeling Study
|
Feenstra, Talitha L.
|
|
2005
|
8 |
3 |
p. 178-190
13 p.
|
artikel
|
| 7 |
CS5 COST OF URINARY INCONTINENCE IN GERMANY: RESULTS FROM PROSPECTIVE URINARY RESEARCH (PURE)
|
Finnern, HW
|
|
2005
|
8 |
3 |
p. 253-254
2 p.
|
artikel
|
| 8 |
CS4 COST-UTILITY OF CATHETERABLATION FOR FIRST-LINE TREATMENT OF ATRIAL FLUTTER
|
Reyes, CM
|
|
2005
|
8 |
3 |
p. 249-250
2 p.
|
artikel
|
| 9 |
CS8 ECONOMIC EVALUATION OF ONDANSETRON VERSUS DIMENHYDRINATE FOR PREVENTION OF POSTOPERATIVE VOMITING IN CHILDREN
|
Piwko, C
|
|
2005
|
8 |
3 |
p. 254-255
2 p.
|
artikel
|
| 10 |
CS2 ECONOMIC IMPACT OF CARDIOVASCULAR EVENTS IN NEWLY DIAGNOSED TYPE-2 DIABETES PATIENTS
|
Rajagopalan, R
|
|
2005
|
8 |
3 |
p. 249-
1 p.
|
artikel
|
| 11 |
CSI ECONOMIC BURDEN OF OSTEOPOROSIS-RELATED FRACTURES IN MEDICAID
|
Rousculp, MD
|
|
2005
|
8 |
3 |
p. 248-249
2 p.
|
artikel
|
| 12 |
CS3 IMPACT OF ESTIMATION TECHNIQUE ON MEDICAL COST ESTIMATES FOR OVERACTIVE BLADDER TREATMENTS
|
Nitz, NM
|
|
2005
|
8 |
3 |
p. 249-
1 p.
|
artikel
|
| 13 |
CS7 OVERCOMING SAMPLE-SELECTION CHALLENGES IN ECONOMIC COMPARISONS OF DRUG AND NON-DRUG THERAPY: THE CASE OF OVERACTIVE BLADDER
|
Ollendorf, DA
|
|
2005
|
8 |
3 |
p. 254-
1 p.
|
artikel
|
| 14 |
CS6 TREATMENT OF INSTITUTIONALIZED PATIENTS WITH ALZHEIMER'S DISEASE WITH QUETIAPINE: A COST-EFFECTIVENESS EVALUATION
|
Getsios, D
|
|
2005
|
8 |
3 |
p. 254-
1 p.
|
artikel
|
| 15 |
CV8 ASSOCIATION BETWEEN LONG-TERM USE OF NSAIDS/ COX-2 INHIBITORSAND CARDIOVASCULAR RISK-A RETROSPECTIVE ANALYSIS USING THE VETERAN AFFAIRS (VA) DATABASE
|
Motsko, SP
|
|
2005
|
8 |
3 |
p. 253-
1 p.
|
artikel
|
| 16 |
CV7 9301 COST-EFFECTIVENESS OF LONG-TERM THERAPY WITH CLOPIDOGREL FOLLOWING PERCUTANEOUS CORONARY INTERVENTION: A SWEDISH ANALYSIS OF THE CREDO-TRIAL
|
Ringborg, A
|
|
2005
|
8 |
3 |
p. 253-
1 p.
|
artikel
|
| 17 |
CV4 CUMULATIVE EXPOSURE TO CYCLOOXYGENASE-2 INHIBITORSAND CARDIOVASCULAR RISK
|
Shaya, FT
|
|
2005
|
8 |
3 |
p. 248-
1 p.
|
artikel
|
| 18 |
CV5 ESTIMATING FLEXIBLE SURVIVAL FUNCTIONS FOR USE IN ECONOMIC MODELING: A CASE-STUDY USING THE CURE TRIAL
|
Caro, JJ
|
|
2005
|
8 |
3 |
p. 252-
1 p.
|
artikel
|
| 19 |
CVI DISCRETE EVENT SIMULATION TO ESTIMATE COST-BENEFIT OF PREVENTING SUDDEN CARDIAC DEATHS WITH AN IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD) VS. AMIODARONE IN FRANCE
|
Deniz, HB
|
|
2005
|
8 |
3 |
p. 247-
1 p.
|
artikel
|
| 20 |
CV2 LIPID LEVELSAND NCEPATP-III LDL-CHOLESTEROL GOAL ATTAINMENT IN PATIENTS NEWLY-INITIATED ON ROSUVASTATIN ORATORVASTATIN
|
Bullano, MF
|
|
2005
|
8 |
3 |
p. 247-248
2 p.
|
artikel
|
| 21 |
CV3 ONE-YEAR COSTS FORACUTE CORONARY SYNDROME- AN INTEGRATED HEALTHCARE SYSTEM PERSPECTIVE
|
Sidney, S
|
|
2005
|
8 |
3 |
p. 248-
1 p.
|
artikel
|
| 22 |
CV6 RISK FACTORS AND OUTCOMES OF SURGICAL SITE INFECTIONS IN DIABETICS UNDERGOING CARDIAC SURGERY
|
Kumar, N
|
|
2005
|
8 |
3 |
p. 253-
1 p.
|
artikel
|
| 23 |
DB5 BODY MASS INDEX (BMI) AND TRENDS IN GP CONSULTATIONS AND PRESCRIBING: A UK NHS PERSPECTIVE
|
Boler, A
|
|
2005
|
8 |
3 |
p. 255-
1 p.
|
artikel
|
| 24 |
DB6 COMPARISON OF THE COST-EFFECTIVENESS FOR BASAL-BOLUS THERAPY OF TYPE-1 DIABETES USING INSULIN DETEMIR+ INSULIN ASPART OR HUMAN INSULIN-BASED REGIMENS IN THE NETHERLANDS
|
Wj, Valentine
|
|
2005
|
8 |
3 |
p. 255-
1 p.
|
artikel
|
| 25 |
DB3 COST-EFFECTIVENESS OF DETECTION OF CAD BY MYOCARDIAL PERFUSION IMAGING IN ASYMPTOMATIC PATIENTS WITH DIABETES
|
Papatheofanis, FJ
|
|
2005
|
8 |
3 |
p. 250-
1 p.
|
artikel
|
| 26 |
DB2 ECONOMIC CONSEQUENCES OF CHOICE OF DIABETES THERAPY IN A MEDICAID POPULATION
|
Kalsekar, I
|
|
2005
|
8 |
3 |
p. 250-
1 p.
|
artikel
|
| 27 |
DB4 HEART FAILURE RISK OFTHIAZOLIDINEDIONES INA MEDICAID MANAGED CARE POPULATION
|
Shaya, FT
|
|
2005
|
8 |
3 |
p. 251-
1 p.
|
artikel
|
| 28 |
DBI ESTIMATION OF THE FINANCIAL IMPACT OF OBESITY ON THE NATIONAL HEALTH SERVICE AND SOCIETY IN THE UNITED KINGDOM
|
Woehl, A
|
|
2005
|
8 |
3 |
p. 250-
1 p.
|
artikel
|
| 29 |
DB7 THE EFFECT OF OBESITY ADJUSTMENTS ON COST-EFFECTIVENESS MODELS OF DIABETES PREVENTION
|
Novak, S
|
|
2005
|
8 |
3 |
p. 255-256
2 p.
|
artikel
|
| 30 |
DB8 THE IMPACT OF GLYCEMIC CONTROL ON THE INCIDENCE OF DIABETIC COMPLICATIONS
|
Taylor, MD
|
|
2005
|
8 |
3 |
p. 256-
1 p.
|
artikel
|
| 31 |
Disclosure Information
|
|
|
2005
|
8 |
3 |
p. 420-425
6 p.
|
artikel
|
| 32 |
DRUG-ELUTING VERSUS BARE-METAL CORONARY STENTS: 6-MONTH CLINICAL AND ECONOMIC OUTCOMES OF A CONTROLLED STUDY FOR THE REDUCTION OF CORONARY RESTENOSIS
|
Brüggenjürgen, BH
|
|
2005
|
8 |
3 |
p. 337-338
2 p.
|
artikel
|
| 33 |
Economic and Utilization Outcomes Associated with Choice of Treatment for Venous Thromboembolism in Hospitalized Patients
|
Knight, Kevin K.
|
|
2005
|
8 |
3 |
p. 191-200
10 p.
|
artikel
|
| 34 |
EMERGENCY DEPARTMENT USE FOR ACUTE ALCOHOL INTOXICATION BY COLLEGE AGE PERSONS: TIME AND COST OF TREATMENT
|
O'Brien, JA
|
|
2005
|
8 |
3 |
p. 385-
1 p.
|
artikel
|
| 35 |
Federal Sponsorship of Cost-Effectiveness and Related Research in Health Care: 1997–2001
|
Siegel, Joanna E.
|
|
2005
|
8 |
3 |
p. 223-236
14 p.
|
artikel
|
| 36 |
FM2 CHANGES IN ADHERENCE FOLLOWING A CO-PAY CHANGE FOR ASTHMA AND DIABETES THERAPIES
|
Meyer, CM
|
|
2005
|
8 |
3 |
p. 251-
1 p.
|
artikel
|
| 37 |
FM4 COX-2 INHIBITOR STEP CARE PROGRAM ON MEDICATION COSTS AND UTILIZATION: RESULTS FROM A PHARMACY BENEFIT MANAGEMENT SETTING
|
Sun, SX
|
|
2005
|
8 |
3 |
p. 252-
1 p.
|
artikel
|
| 38 |
FMI PRESCRIPTION DRUG COST-SHARING AND ANTICOAGULANT DRUG USE-UNINTENDED EFFECTS OF THINNER BENEFITS
|
Hsu, J
|
|
2005
|
8 |
3 |
p. 251-
1 p.
|
artikel
|
| 39 |
FM3 PRESCRIPTION DRUG COPAYMENTS, MAIL ORDER SUBSTITUTION AND STOCKPILING OF MAINTENANCE MEDICATIONS
|
Gibson, TB
|
|
2005
|
8 |
3 |
p. 252-
1 p.
|
artikel
|
| 40 |
Forward
|
Mauskopf, Josephine
|
|
2005
|
8 |
3 |
p. 177-
1 p.
|
artikel
|
| 41 |
HP7 AN EVALUATION OF PHARMACEUTICAL PRICES UNDERTHE PHARMACEUTICAL FEDERAL SUPPLY SCHEDULE
|
Bhandary, D
|
|
2005
|
8 |
3 |
p. 243-
1 p.
|
artikel
|
| 42 |
HP6 CHOLESTEROL GOAL ATTAINMENT AMONG CHD PATIENTS IN HONG KONG
|
Lee, VW
|
|
2005
|
8 |
3 |
p. 242-
1 p.
|
artikel
|
| 43 |
HP2 EFFECTS OF PATIENTS' BELIEFS ABOUT MEDICATIONS ON NON-ADHERENCE TO CHRONIC MEDICATIONS
|
Phatak, HM
|
|
2005
|
8 |
3 |
p. 237-
1 p.
|
artikel
|
| 44 |
HP5 FINANCIAL BARRIERS TO MEDICATION USE IN CHILDREN WITH ASTHMA: AN ANALYSIS OF PRIVATE SECTOR PRESCRIPTION MEDICATION CLAIMS
|
Ungar, WJ
|
|
2005
|
8 |
3 |
p. 242-
1 p.
|
artikel
|
| 45 |
HP8 FINANCIAL IMPACT OF A PRIOR-AUTHORIZATION RESTRICTION FOR PIMECROLIMUS 1% CREAM IN THE TREATMENT OF ATOPIC DERMATITIS
|
Mahajan, S
|
|
2005
|
8 |
3 |
p. 243-
1 p.
|
artikel
|
| 46 |
HPI MEDICAID DRUG SPENDING AFTER THE MEDICARE MODERNIZATION ACT: WHAT WILL BE LEFT?
|
Boulanger, L
|
|
2005
|
8 |
3 |
p. 237-
1 p.
|
artikel
|
| 47 |
HP4 POTENTIALLY INAPPROPRIATE MEDICATION PRESCRIBING FOR ELDERLY AMBULATORY PATIENTS IN REGIONE EMILIA ROMAGNA, ITALY
|
Maio, V
|
|
2005
|
8 |
3 |
p. 238-
1 p.
|
artikel
|
| 48 |
HP3 WHO WILL REQUEST A SWITCH TO NEW TREATMENT AS A RESULT OF DIRECT-TO-CONSUMERADVERTISING?
|
Chen, HD
|
|
2005
|
8 |
3 |
p. 237-238
2 p.
|
artikel
|
| 49 |
IN3 COSTS OF DELIVERING ADULT INFLUENZA VACCINATION IN NON-TRADITIONAL SETTINGS
|
Presser, LA
|
|
2005
|
8 |
3 |
p. 244-
1 p.
|
artikel
|
| 50 |
INI COMPARISON OF RISK FACTORS FOR BLOOD STREAM CANDIDEMIA AND BACTEREMIA IN HOSPITALIZED PATIENTS
|
Amrutkar, PP
|
|
2005
|
8 |
3 |
p. 243-
1 p.
|
artikel
|
| 51 |
INI COST EFFECTIVENESS OF HIVTREATMENT INNOVATIONS OF GREATER EFFICACY THAN HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
|
Snedecor, SJ
|
|
2005
|
8 |
3 |
p. 244-
1 p.
|
artikel
|
| 52 |
IN2 SIMULATION OF A PROPOSED TRIAL TO EVALUATE THE COST-EFFECTIVENESS OF USING A COMBINATION REGIMEN FOR THE TREATMENT OF ACUTE SINUSITIS
|
Pezzullo, JC
|
|
2005
|
8 |
3 |
p. 243-244
2 p.
|
artikel
|
| 53 |
Managing Prices for Hospital Pharmaceuticals: A Successful Strategy for New Zealand?
|
Tordoff, June M.
|
|
2005
|
8 |
3 |
p. 201-208
8 p.
|
artikel
|
| 54 |
MC4 CHOOSING BETWEEN SFI2/SF-36 PREFERENCE-BASED ALGORITHMS FOR COST-UTILITY ANALYSIS
|
Pickard, AS
|
|
2005
|
8 |
3 |
p. 240-
1 p.
|
artikel
|
| 55 |
MC3 DOES METHOD OF CASE ASCERTAINMENT AFFECT ESTIMATES OF THE PREVALENCE AND SEVERITY OF DEMENTIA IN MEDICARE NURSING HOME RESIDENTS?
|
Singhal, PK
|
|
2005
|
8 |
3 |
p. 240-
1 p.
|
artikel
|
| 56 |
MC2 EVALUATION OF MEDICATION ADHERENCE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
|
Kim, JW
|
|
2005
|
8 |
3 |
p. 240-
1 p.
|
artikel
|
| 57 |
MCI WHY DO DIFFERENT MODELS COME TO DIFFERENT CONCLUSIONS?: A STUDY OF 8 COST-EFFECTIVENESS ANALYSES COMPARING COX-2 SPECIFIC INHIBITORS (COXIBS) AND NON STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
|
Risebrough, NA
|
|
2005
|
8 |
3 |
p. 239-240
2 p.
|
artikel
|
| 58 |
MH4 EFFECT OF SECOND-GENERATION ANTIDEPRESSANT DISCONTINUATION ON DEPRESSIVE RELAPSE IN ADULT PATIENTS WITH BIPOLAR DEPRESSION
|
Fu, AZ
|
|
2005
|
8 |
3 |
p. 257-
1 p.
|
artikel
|
| 59 |
MHI TREATMENT COSTS OF ALZHEIMER'S DISEASE IN THE CALIFORNIA MEDICAID (MEDI-CAL) PROGRAM FROM 1995 TO 2002
|
Lee, LJ
|
|
2005
|
8 |
3 |
p. 256-
1 p.
|
artikel
|
| 60 |
MH3 SUPPORT FOR CLASSIFICATION OF DEPRESSION OUTCOMES INTO LONGITUDINAL PATTERNS: EVIDENCE FROM A POPULATION-BASED STUDY OF THE ELDERLY
|
Dalai, MR
|
|
2005
|
8 |
3 |
p. 257-
1 p.
|
artikel
|
| 61 |
MS2 CARDIOVASCULAR RISK FACTORS AT BASELINE IN USERS OF COXIBS COMPARED TO USERS OF NSAIDS
|
De Jong, RB
|
|
2005
|
8 |
3 |
p. 241-
1 p.
|
artikel
|
| 62 |
MS3 ECONOMIC EVALUATION OF CONTROLLED-RELEASE OXYCODONE (OXYCONTIN®TABLETS) (CRO) VERSUS OXYCODONE/ACETAMINOPHEN (PERCOCET®) (OXY/APAP) FOR OSTEOARTHRITIS PAIN OF THE HIP OR KNEE
|
Marshall, DA
|
|
2005
|
8 |
3 |
p. 241-
1 p.
|
artikel
|
| 63 |
MSI PARENTERAL PARECOXIB FOLLOWED BY ORAL VALDECOXIB AFTER MAJOR GENERAL SURGERY REDUCES OPIOID CONSUMPTION AND OPIOID-RELATED SYMPTOMS
|
Katz, JA
|
|
2005
|
8 |
3 |
p. 241-
1 p.
|
artikel
|
| 64 |
MS4 THE COST-EFFECTIVENESS OF ADDING INFLIXIMAB TO USUAL THERAPY IN THE TREATMENT OF PSORIATIC ARTHRITIS
|
Marra, CA
|
|
2005
|
8 |
3 |
p. 242-
1 p.
|
artikel
|
| 65 |
PAL2 PATIENT PERCEPTIONS REGARDING THE USE OF OVER-THE-COUNTER CLARITIN
|
Nair, KV
|
|
2005
|
8 |
3 |
p. 339-
1 p.
|
artikel
|
| 66 |
PAL1 THE IMPACT OF THE RX-TO-OTC SWITCH OF LORATADINE AND CHANGES IN PRESCRIPTION DRUG BENEFITS ON UTILIZATION AND COST OF THERAPY
|
Sullivan, P
|
|
2005
|
8 |
3 |
p. 339-
1 p.
|
artikel
|
| 67 |
PAL1 THE IMPACT OF THE RX-TO-OTC SWITCH OF LORATADINE AND CHANGES IN PRESCRIPTION DRUG BENEFITS ON UTILIZATION AND COST OF THERAPY
|
Sullivan, P
|
|
2005
|
8 |
3 |
p. 338-339
2 p.
|
artikel
|
| 68 |
PAL3 WILLINGNESS TO PAY FOR INTRANASAL CORTICOSTEROID THERAPY:THE IMPORTANCE OF SENSORY ATTRIBUTES
|
Kleinman, L
|
|
2005
|
8 |
3 |
p. 339-340
2 p.
|
artikel
|
| 69 |
PAR12 ABATACEPT (CTLA4IG) IN COMBINATION WITH METHOTREXATE DEMONSTRATES SUSTAINED IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES OVER TWO YEARS IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE
|
Li, T
|
|
2005
|
8 |
3 |
p. 343-
1 p.
|
artikel
|
| 70 |
PAR8 ALTERNATIVE DECISION ANALYSIS MODELING IN THE ECONOMIC EVALUATION OF TUMOR NECROSIS FACTOR INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS
|
Kamal, KM
|
|
2005
|
8 |
3 |
p. 342-
1 p.
|
artikel
|
| 71 |
PAR4 A REVIEW OF TOTAL COST BURDEN OF FIBROMYALGIA
|
Larsen, T
|
|
2005
|
8 |
3 |
p. 340-341
2 p.
|
artikel
|
| 72 |
PAR5 DEVELOPMENT OF BENCHMARK METHODOLOGY TO IDENTIFY GOUT PATIENTS AND GOUT ATTACKS FROM A RETROSPECTIVE DATABASE ANALYSIS
|
Brewer, K
|
|
2005
|
8 |
3 |
p. 341-
1 p.
|
artikel
|
| 73 |
PAR9 EFFECTS OF ADALIMUMAB MONOTHERAPY ON HEALTH UTILITY AND FATIGUE IN PATIENTS WITH LONG-STANDING, SEVERE RHEUMATOID ARTHRITIS (RA)
|
Mittendorf, T
|
|
2005
|
8 |
3 |
p. 342-
1 p.
|
artikel
|
| 74 |
PAR6 HEALTH CARE UTILIZATION AND DIRECT MEDICAL COSTS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN AN DEVELOPING COUNTRY
|
Soriano, ER
|
|
2005
|
8 |
3 |
p. 341-
1 p.
|
artikel
|
| 75 |
PAR10 SATISFACTION WITH PAIN MEDICATION AND INTENTION TO COMPLY WITH TREATMENT: A STRUCTURAL EQUATION MODEL IN RHEUMATOID ARTHRITIS PATIENTS
|
Evans, CJ
|
|
2005
|
8 |
3 |
p. 342-343
2 p.
|
artikel
|
| 76 |
PAR7 SURVEY OF CURRENT TREATMENT PRACTICES OF RHEUMATOLOGISTS IN PRESCRIBING TUMOR NECROSIS FACTOR INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS
|
Kamal, KM
|
|
2005
|
8 |
3 |
p. 341-342
2 p.
|
artikel
|
| 77 |
PAR3 TESTING THE BMJ CHECKLIST AS A QUALITY ASSESSMENT TOOL FOR ECONOMIC EVALUATIONS
|
Drummond, M
|
|
2005
|
8 |
3 |
p. 340-
1 p.
|
artikel
|
| 78 |
PAR11 THE IMPACT OF DEPRESSION ON RHEUMATOID ARTHRITIS PATIENT QUALITY OF LIFE
|
Zhang, L
|
|
2005
|
8 |
3 |
p. 343-
1 p.
|
artikel
|
| 79 |
PAR2 THE IMPACT OF SPECIALTY CARE ON THE UTILIZATION OF NEW DRUGS: THE CASE OF COX-2 SELECTIVE INHIBITORS
|
De Smet, BD
|
|
2005
|
8 |
3 |
p. 340-
1 p.
|
artikel
|
| 80 |
PAS3 A COMPARISON OF ASTHMA MEDICATION USE IN PUBLICLY VERSUS PRIVATELY INSURED CHILDREN WITH ASTHMA
|
Ungar, WJ
|
|
2005
|
8 |
3 |
p. 258-259
2 p.
|
artikel
|
| 81 |
PAS8 A DYAD APPROACH TO QUALITY OF LIFE MEASUREMENT IN CHILDREN WITH ASTHMA
|
Mirabelli, C
|
|
2005
|
8 |
3 |
p. 260-
1 p.
|
artikel
|
| 82 |
PAS9 CHOOSING AMONG DIFFERENT TYPES OF MATCHING TECHNIQUES
|
Baser, O
|
|
2005
|
8 |
3 |
p. 260-
1 p.
|
artikel
|
| 83 |
PAS7 DIRECT AND INDIRECT COST OF ASTHMA IN AN EMPLOYER POPULATION
|
Atherly, A
|
|
2005
|
8 |
3 |
p. 259-260
2 p.
|
artikel
|
| 84 |
PAS5 DRUG COST ANALYSIS OF TREATMENT FOR ASTHMA OUTPATIENTS IN TAIWAN
|
Lu, CH
|
|
2005
|
8 |
3 |
p. 259-
1 p.
|
artikel
|
| 85 |
PASI HEALTH CARE UTILIZATION, COST AND MEDICATION USE AMONG PEDIATRIC ASTHMA PATIENTS
|
Modi, A
|
|
2005
|
8 |
3 |
p. 258-
1 p.
|
artikel
|
| 86 |
PAS2 IMPACT OF ANTI-INFLAMMATORY MEDICATION ON ASTHMA COSTS IN A PEDIATRIC POPULATION
|
Sapra, SJ
|
|
2005
|
8 |
3 |
p. 258-
1 p.
|
artikel
|
| 87 |
PAS6 IMPACT OF ASTHMA KNOWLEDGE ON HEALTH OUTCOMES IN PEDIATRIC PATIENTS
|
Suksomboon, N
|
|
2005
|
8 |
3 |
p. 259-
1 p.
|
artikel
|
| 88 |
PAS4 PATTERNS OF PHARMACOTHERAPY UTILIZATION AMONG CHILDREN AND ADOLESCENTS WITH MULTIPLE ASTHMA-RELATED MORBID EVENTS ENROLLED IN A MEDICAID PROGRAM
|
D'Souza, AO
|
|
2005
|
8 |
3 |
p. 259-
1 p.
|
artikel
|
| 89 |
PCN17 ASSESSMENT OF BREAST CANCER KNOWLEDGE, SCREENING BEHAVIOR, RISK PERCEPTIONS, AND
|
Borker, RD
|
|
2005
|
8 |
3 |
p. 348-349
2 p.
|
artikel
|
| 90 |
PCN20 A SYSTEMATIC REVIEW OF PHYSICIAN KNOWLEDGE AND PRACTICE PATTERNS REGARDING COLORECTAL CANCER SCREENING
|
Khanna, R
|
|
2005
|
8 |
3 |
p. 349-350
2 p.
|
artikel
|
| 91 |
PCN5 BUDGET IMPACT ANALYSIS OF INTRAVENOUS (IV) ZOLEDRONIC ACID VS. ORAL IBANDRONATE OR IV GENERIC PAMIDRONATE IN THE PREVENTION OF BONE COMPLICATIONS IN BREAST CANCER PATIENTS WITH BONE METASTASES: A UK NHS PERSPECTIVE
|
Botteman, M
|
|
2005
|
8 |
3 |
p. 345-
1 p.
|
artikel
|
| 92 |
PCN26 DERIVING A PREFERENCE-BASED INDEX FROM THE MD ANDERSON SYMPTOM INVENTORY IN CANCER PATIENTS
|
Shih, YCT
|
|
2005
|
8 |
3 |
p. 351-352
2 p.
|
artikel
|
| 93 |
PCN4 ECONOMIC EVALUATION OF INTRAVENOUS (IV) ZOLEDRONIC ACID VS. OTHER IV BISPHOSPHONATES IN THE PREVENTION OF BONE COMPLICATIONS IN BREAST CANCER PATIENTS WITH BONE METASTASES: A UK BUDGET IMPACT ANALYSIS
|
Botteman, M
|
|
2005
|
8 |
3 |
p. 344-
1 p.
|
artikel
|
| 94 |
PCN10 ECONOMIC IMPACT OF PROSTATE-SPECIFIC ANTIGEN DOUBLING TIME IN PATIENTS WITH HORMONEREFRACTORY PROSTATE CANCER
|
Mulani, P
|
|
2005
|
8 |
3 |
p. 346-
1 p.
|
artikel
|
| 95 |
PCN6 ECONOMICS OF PRIMARY & SECONDARY BREAST CANCER PREVENTIVE STRATEGIES: A DECISION MODEL
|
Borker, RD
|
|
2005
|
8 |
3 |
p. 345-
1 p.
|
artikel
|
| 96 |
PCN12 ESTIMATING COSTS OF UNCONTROLLED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING AMONG WORKING-AGE CANCER PATIENTS
|
Shih, YCT
|
|
2005
|
8 |
3 |
p. 347-
1 p.
|
artikel
|
| 97 |
PCN22 ESTIMATION OF CENSORED MEDICAL COUNT DATA
|
Baser, O
|
|
2005
|
8 |
3 |
p. 350-
1 p.
|
artikel
|
| 98 |
PCN24 HANDLING MISSING PATIENT REPORTED OUTCOMES (PRO) DATA FOR PREMATURE WITHDRAWALS FROM CLINICAL TRIALS OF SEVERE DISEASES
|
Crawford, B
|
|
2005
|
8 |
3 |
p. 351-
1 p.
|
artikel
|
| 99 |
PCN27 INCONGRUENT DEFINITIONS OF RISK AND UNCERTAINTY AMONG CLINICAL ONCOLOGISTS AND ITS IMPLICATIONS FOR DECISION MAKING
|
Molnar, R
|
|
2005
|
8 |
3 |
p. 352-
1 p.
|
artikel
|
| 100 |
PCN14 IS COMBINED ANDROGEN BLOCKADE WITH BICALUTAMIDE COST-EFFECTIVE COMPARED WITH COMBINED ANDROGEN BLOCKADE WITH FLUTAMIDE?
|
Ramsey, S
|
|
2005
|
8 |
3 |
p. 347-348
2 p.
|
artikel
|
| 101 |
PCN1 META-ANALYSIS OF THE DIAGNOSTIC ACCURACY OF SCREENING TESTS FOR COLORECTAL CANCER
|
Slivinskas, JC
|
|
2005
|
8 |
3 |
p. 343-
1 p.
|
artikel
|
| 102 |
PCN18 OPIOID USE IN A LARGE NATIONAL HOSPICE POPULATION: EXAMINATION OF CANCER VERSUS NON-CANCER PATIENTS
|
Weston, C
|
|
2005
|
8 |
3 |
p. 349-
1 p.
|
artikel
|
| 103 |
PCN25 RELIABILITY AND VALIDITY OF BRAZILIAN PORTUGUESE HEALTH UTILITIES INDEX (HUI) QUESTIONNAIRES FOR ASSESSING THE HEALTH STATUS OF SURVIVORS OF CHILDHOOD CANCER
|
Horsman, JR
|
|
2005
|
8 |
3 |
p. 351-
1 p.
|
artikel
|
| 104 |
PCN23 RELIABILITY OF SPANISH-LANGUAGE HUI MEASUREMENTS IN SURVIVORS OF CANCER IN CHILDHOOD:AGREEMENT BETWEEN PATIENTS, PARENTS, AND PHYSICIANS
|
Talsma, D
|
|
2005
|
8 |
3 |
p. 350-351
2 p.
|
artikel
|
| 105 |
PCN15 RESOURCE UTILIZATION AMONG PROSTATE CANCER PATIENTS WITH BONE PAIN
|
Kurth, H
|
|
2005
|
8 |
3 |
p. 348-
1 p.
|
artikel
|
| 106 |
PCN21 RETRANSFORMATION OF ESTIMATED LOG-TRANSFORMED COSTS WHEN THE ERRORS PRESENT HETEROSKEDASTICITY
|
Baser, O
|
|
2005
|
8 |
3 |
p. 350-
1 p.
|
artikel
|
| 107 |
PCN2 SURVIVAL ANALYSIS OF PAIN RELIEF PROVIDED BY DOXEPIN ORAL RINSE FOR ORAL MUCOSITIS PATIENTS
|
Epstein, JD
|
|
2005
|
8 |
3 |
p. 344-
1 p.
|
artikel
|
| 108 |
PCN13 SURVIVAL AND COST FOLLOWING BREAST CANCER RECURRENCE: ESTIMATES FROM SEER-MEDICARE DATA
|
Thompson, D
|
|
2005
|
8 |
3 |
p. 347-
1 p.
|
artikel
|
| 109 |
PCN16 THE CLINICAL OUTCOMES AND COSTS OF TREATING ONCOLOGY PATIENTS FOR SEVERE SEPSIS
|
King, KM
|
|
2005
|
8 |
3 |
p. 348-
1 p.
|
artikel
|
| 110 |
PCN7 THE COST-EFFECTIVENESS OF CAPECITABINE AS ADJUVANT ORAL CHEMOTHERAPY FOR DUKE'S C COLON CANCER
|
Garrison, L
|
|
2005
|
8 |
3 |
p. 345-
1 p.
|
artikel
|
| 111 |
PCN9 THE COST-EFFECTIVENESS OF HERCEPTIN® IN ADJUVANT SETTING: THE HERA TRIAL
|
Neyt, M
|
|
2005
|
8 |
3 |
p. 346-
1 p.
|
artikel
|
| 112 |
PCN8 THE COST-EFFECTIVENESS OF PROSTATE-SPECIFIC ANTIGEN SCREENING FOR PROSTATE CANCER DETECTION
|
Tencer, T
|
|
2005
|
8 |
3 |
p. 346-
1 p.
|
artikel
|
| 113 |
PCN11 THE COST OF CANCER IN KOREA: 1999–2003
|
Jung, YH
|
|
2005
|
8 |
3 |
p. 346-347
2 p.
|
artikel
|
| 114 |
PCN3 TIME TO CANCER DIAGNOSIS (TDX) IN YOUNG AMERICANS DEPENDS ON TYPE OF CANCER AND HEALTH INSURANCE STATUS
|
Martin, SK
|
|
2005
|
8 |
3 |
p. 344-
1 p.
|
artikel
|
| 115 |
PCN19 VARIATIONS IN INPATIENT PROSTATE CANCER TREATMENT IN FLORIDA
|
Campbell, ES
|
|
2005
|
8 |
3 |
p. 349-
1 p.
|
artikel
|
| 116 |
PCV38 A COMPARISON OF THE ELIXHAUSER AND CHARLSON INDICES TO CONTROL FOR CONFOUNDING IN HEALTH OUTCOMES STUDIES
|
Farley, J
|
|
2005
|
8 |
3 |
p. 272-
1 p.
|
artikel
|
| 117 |
PCV2 ACUTE CORONARY SYNDROMES: ONE YEAR COSTS AND OUTCOMES
|
Taylor, M
|
|
2005
|
8 |
3 |
p. 261-
1 p.
|
artikel
|
| 118 |
PCV42 ADHERENCE TO ANTIHYPERTENSIVE MEDICATIONS RELATED TO COPAYMENT LEVEL
|
Taira, DA
|
|
2005
|
8 |
3 |
p. 273-
1 p.
|
artikel
|
| 119 |
PCV49 ADVANTAGES AND LIMITATIONS OF USING A WEB-BASED SURVEY TO OBTAIN PATIENT-REPORTED OUTCOMES
|
Chen, KS
|
|
2005
|
8 |
3 |
p. 275-276
2 p.
|
artikel
|
| 120 |
PCV52 A MULTI-COUNTRY HEALTH ECONOMIC EVALUATION OF N-3 POLYUNSATURATED FATTY ACIDS (PUFA) IN THE SECONDARY PREVENTION AFTER MI
|
Lamotte, M
|
|
2005
|
8 |
3 |
p. 276-277
2 p.
|
artikel
|
| 121 |
PCV27 AN ECONOMIC ANALYSIS OF EZETIMIBE/SIMVASTATIN COMPARED TO USUAL CARE WITH STATIN MONOTHERAPY
|
Nag, SS
|
|
2005
|
8 |
3 |
p. 268-269
2 p.
|
artikel
|
| 122 |
PCV45 ANTIHYPERTENSIVE THERAPY AFTER ALLHAT: ARE MORE PATIENTS STARTING WITH DIURETICS?
|
Petrilla, AA
|
|
2005
|
8 |
3 |
p. 274-
1 p.
|
artikel
|
| 123 |
PCV48 ASSESSMENT OF THE VALIDITY OF TWO CLAIMS-BASED ALGORITHMS IN IDENTIFYING HYPERTENSIVE PATIENTS
|
Bullano, MF
|
|
2005
|
8 |
3 |
p. 275-
1 p.
|
artikel
|
| 124 |
PCV17 CAREMARK CAREPATTERNS®HEART FAILURE HOME MONITORING PROGRAM IMPROVES PARTICIPANTS' HOME MONITORING COMPLIANCE
|
Fensterheim, LE
|
|
2005
|
8 |
3 |
p. 265-266
2 p.
|
artikel
|
| 125 |
PCV36 CHOLESTEROL GOAL ATTAINMENT IN DYSLIPIDEMIC TREATED PATIENTS AND INCIDENCE OF CARDIOVASCULAR EVENTS IN CLINICAL PRACTICE
|
Van Ganse, E
|
|
2005
|
8 |
3 |
p. 271-272
2 p.
|
artikel
|
| 126 |
PCV58 CLINICAL AND ECONOMIC ISSUES IN THE PREVENTION OF VENOUS THROMBOEMBOLISM IN HOSPITALIZED ORTHOPEDIC PATIENTS: ENOXAPARIN VERSUS WARFARIN
|
Balu, S
|
|
2005
|
8 |
3 |
p. 278-279
2 p.
|
artikel
|
| 127 |
PCV1 COMPARISON OF ALTERNATIVE STRATEGIES FOR THE DIAGNOSIS OF ACUTE CARDIAC ISCHEMIA IN EMERGENCY DEPARTMENTS: STANDARD OF CARE VERSUS BMIPP
|
Wu, EQ
|
|
2005
|
8 |
3 |
p. 260-261
2 p.
|
artikel
|
| 128 |
PCV53 COST ANALYSIS ON ANTICOAGULANT DRUG MARKET
|
He, J
|
|
2005
|
8 |
3 |
p. 277-
1 p.
|
artikel
|
| 129 |
PCV13 COST-EFFECTIVENESS EVALUATION OF EPLERENONE IN PATIENTS WITH HEART FAILURE FOLLOWING AMI IN GERMANY
|
Kvasz, M
|
|
2005
|
8 |
3 |
p. 264-
1 p.
|
artikel
|
| 130 |
PCV9 COST-EFFECTIVENESS OF AMIODARONE TO PREVENT ATRIAL FIBRILLATION AFTER CARDIAC SURGERY
|
Reddy, P
|
|
2005
|
8 |
3 |
p. 263-
1 p.
|
artikel
|
| 131 |
PCV25 COST EFFECTIVENESS OF ATORVASTATIN (LIPITOR) AS SINGLE THERAPY AND DUAL THERAPY WITH EZETIMIBE (ZETIA)
|
Bui, T
|
|
2005
|
8 |
3 |
p. 268-
1 p.
|
artikel
|
| 132 |
PCV26 COST-EFFECTIVENESS OF EZETIMIBE CO-ADMINISTRATION IN CHD PATIENTS NOT AT GOAL WITH CURRENT STATIN THERAPY IN HONG KONG
|
Lee, VW
|
|
2005
|
8 |
3 |
p. 268-
1 p.
|
artikel
|
| 133 |
PCV57 COST OF MAJOR BLEEDING FOLLOWING MAJOR ORTHOPEDIC SURGERY
|
Vera-Llonch, M
|
|
2005
|
8 |
3 |
p. 278-
1 p.
|
artikel
|
| 134 |
PCV28 COST-UTILITY ANALYSIS FOR STATINS IN MEXICO
|
Mould Quevedo, JF
|
|
2005
|
8 |
3 |
p. 269-
1 p.
|
artikel
|
| 135 |
PCV12 DATA CAPTURE VIA INTERACTIVE VOICE RESPONSE SYSTEM IN A NATIONAL STUDY OF ANTICOAGULATION MANAGEMENT
|
Payne, K
|
|
2005
|
8 |
3 |
p. 264-
1 p.
|
artikel
|
| 136 |
PCV20 DECREASING HOSPITALIZATIONS FOR HEART FAILURE IN BRITISH COLUMBIA, CANADA, 1993-2001
|
Levy, A
|
|
2005
|
8 |
3 |
p. 266-
1 p.
|
artikel
|
| 137 |
PCV31 DOES PLAN DESIGN AFFECT THERAPY ADHERENCE FOR CHRONIC CONDITIONS?
|
Matlin, OS
|
|
2005
|
8 |
3 |
p. 270-
1 p.
|
artikel
|
| 138 |
PCV54 ECONOMIC AND HUMANISTIC BURDEN OF POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE IN GERMANY
|
Brüggenjürgen, BH
|
|
2005
|
8 |
3 |
p. 277-
1 p.
|
artikel
|
| 139 |
PCV21 EFFECTIVENESS OF CLINICAL PATHWAYS FOR INPATIENT HEARTH FAILURE TREATMENT: RESULTS OF A MULTICENTER CONTROLLED TRIAL
|
Panella, M
|
|
2005
|
8 |
3 |
p. 267-
1 p.
|
artikel
|
| 140 |
PCV35 EFFECT OF CLINICAL PHARMACIST INTERVENTION ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) OUTCOMES IN AN AMBULATORY SETTING
|
Guy-Alfandary, S
|
|
2005
|
8 |
3 |
p. 271-
1 p.
|
artikel
|
| 141 |
PCV34 EFFECT OF CO-PAYMENT ON THE INITIATION OF STATINS AFTER CORONARY HEART DISEASE HOSPITALIZATION
|
Ye, X
|
|
2005
|
8 |
3 |
p. 271-
1 p.
|
artikel
|
| 142 |
PCV23 EVALUATING THE DIAGNOSTIC VALIDITY OF ADMINISTRATIVE CLAIMS DATA FOR COMMON CHRONIC DISEASES
|
Yu, YF
|
|
2005
|
8 |
3 |
p. 267-
1 p.
|
artikel
|
| 143 |
PCV56 EVALUATION AND COMPARISON OF DIFFERENT MODELS OF METABOLIC SYNDROME USING CONFIRMATORY FACTOR ANALYSIS
|
Shah, S
|
|
2005
|
8 |
3 |
p. 278-
1 p.
|
artikel
|
| 144 |
PCV32 EVALUATION OF FACTORS RELATED TO DIAGNOSIS OF HYPERLIPIDEMIA: THE ROLE OF DIRECT-TO-CONSUMER ADVERTISING EXPENDITURES, HEALTH INSURANCE COVERAGE, AGE AND GENDER
|
Nair, R
|
|
2005
|
8 |
3 |
p. 270-
1 p.
|
artikel
|
| 145 |
PCV22 HEALTH AND ECONOMIC BURDEN OF POOR MEDICATION ADHERENCE IN THE UNITED STATES
|
Thompson, D
|
|
2005
|
8 |
3 |
p. 267-
1 p.
|
artikel
|
| 146 |
PCV7 HEALTH CARE RESOURCE UTILIZATION AND COST OF ATRIAL FLUTTER PATIENTS
|
Pelletier, E
|
|
2005
|
8 |
3 |
p. 262-263
2 p.
|
artikel
|
| 147 |
PCV16 INCREMENTAL EFFECTS OF CONCURRENT PHARMACOTHERAPEUTIC REGIMENS FOR HEART FAILURE ON HOSPITALIZATIONS AND COSTS
|
Skrepnek, GH
|
|
2005
|
8 |
3 |
p. 265-
1 p.
|
artikel
|
| 148 |
PCV43 INSURANCE COVERAGE AND AMBULATORY CARE OF HYPERTENSION FOR THE NEAR ELDERLY
|
Raofi, S
|
|
2005
|
8 |
3 |
p. 274-
1 p.
|
artikel
|
| 149 |
PCV6 LONG-TERM COST-EFFECTIVENESS OF EARLY AND SUSTAINED DUAL ORAL ANTIPLATELET THERAPY WITH CLOPIDOGREL FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (CREDO TRIAL): A FOUR-EUROPEAN COUNTRY ANALYSIS
|
Weintraub, WS
|
|
2005
|
8 |
3 |
p. 262-
1 p.
|
artikel
|
| 150 |
PCV4 LONG-TERM THIENOPYRIDINE THERAPY IN ACS PATIENTS RESIDING IN THE UNITED KINGDOM
|
McCollam, PL
|
|
2005
|
8 |
3 |
p. 261-262
2 p.
|
artikel
|
| 151 |
PCV14 MODELING THE ECONOMIC CONSEQUENCES OF CARDIAC RESYNCHRONIZATION THERAPY IN THE UK
|
Caro, JJ
|
|
2005
|
8 |
3 |
p. 264-265
2 p.
|
artikel
|
| 152 |
PCV30 MONITORING OF LIPID LEVELS AND ADVERSE EVENTS AMONG TEXAS MEDICAID PATIENTS ON STATIN THERAPY
|
Dastani, H
|
|
2005
|
8 |
3 |
p. 269-270
2 p.
|
artikel
|
| 153 |
PCV33 MONITORING OF LIPID LEVELS AND ADVERSE EVENTS AMONG TEXAS MEDICAID PATIENTS ON STATIN THERAPY
|
Dastani, H
|
|
2005
|
8 |
3 |
p. 270-271
2 p.
|
artikel
|
| 154 |
PCV41 PATIENT EDUCATION AND ADHERENCE AND HYPERTENSION CONTROL IN TWO ACADEMIC MEDICAL CENTER PRIMARY CARE PRACTICES
|
Crawford, A
|
|
2005
|
8 |
3 |
p. 273-
1 p.
|
artikel
|
| 155 |
PCV40 PHARMACOECONOMIC EVALUATION OF ANTIHYPERTENSIVE THERAPY IN OLABISI ONABANJO UNIVERSITY TEACHING HOSPITAL, SAGAMU, OGUN SATATE, NIGERIA
|
Suleiman, IA
|
|
2005
|
8 |
3 |
p. 273-
1 p.
|
artikel
|
| 156 |
PCV44 PHYSICAL INACTIVITY IS ASSOCIATED WITH INCREASED HEALTH CARE USE AND EXPENDITURES IN INDIVIDUALS WITH HYPERTENSION
|
Iyer, R
|
|
2005
|
8 |
3 |
p. 274-
1 p.
|
artikel
|
| 157 |
PCV5 POTENTIAL COST SAVINGS FROM ACUTE CORONARY SYNDROME TREATMENT IMPROVEMENTS
|
Klein, RW
|
|
2005
|
8 |
3 |
p. 262-
1 p.
|
artikel
|
| 158 |
PCV15 POTENTIAL MEDICAL COST OFFSETS OF TREATMENT WITH ISOSRBIDE DINITRATE PLUS HYDRALAZINE IN AFRICAN AMERICANS WITH HEART FAILURE
|
Becker, R
|
|
2005
|
8 |
3 |
p. 265-
1 p.
|
artikel
|
| 159 |
PCV37 PREDICTING STATIN COMPLIANCE IN NEW STARTERS WITH PHARMACY CLAIMS
|
Thiebaud, P
|
|
2005
|
8 |
3 |
p. 272-
1 p.
|
artikel
|
| 160 |
PCV29 PREDICTORS OF COMPLIANCE AND PERSISTENCE TO STATIN THERAPY AMONG TEXAS MEDICAID PATIENTS
|
Dastani, H
|
|
2005
|
8 |
3 |
p. 269-
1 p.
|
artikel
|
| 161 |
PCV39 PREVALENCE, AWARENESS AND CONTROL OF HYPERTENSION AMONG LATINOS IN LOS ANGELES COUNTY, CA, USA: ESTIMATES FROM THE LOS ANGELES LATINO EYE STUDY
|
Bonnet, PO
|
|
2005
|
8 |
3 |
p. 272-273
2 p.
|
artikel
|
| 162 |
PCV55 PREVALENCE OF METABOLIC SYMDROME IN KOREAN AMERICANS IN THE UNITED STATES
|
Lee, J
|
|
2005
|
8 |
3 |
p. 277-278
2 p.
|
artikel
|
| 163 |
PCV11 QUALITY OF ANTICOAGULATION CONTROL IN PATIENTS WITH ATRIAL FIBRILLATION MANAGED IN ROUTINE MEDICAL CARE IN THE UNITED STATES
|
Ansell, JE
|
|
2005
|
8 |
3 |
p. 264-
1 p.
|
artikel
|
| 164 |
PCV10 RACE AND GENDER COST DIFFERENCES ASSOCIATED WITH COMORBID ATRIAL FIBRILLATION IN THE HOSPITAL
|
Coyne, KS
|
|
2005
|
8 |
3 |
p. 263-
1 p.
|
artikel
|
| 165 |
PCV51 SHORT AND LONG-TERM COST-EFFECTIVENESS OF EARLY AND SUSTAINED DUAL ORAL ANTIPLATELET THERAPY WITH CLOPIDROGREL FOLLOWING PERCUTANEOUS CORONARY INTERVENTION:A CANADIAN ECONOMIC ANALYSIS
|
Kolm, P
|
|
2005
|
8 |
3 |
p. 276-
1 p.
|
artikel
|
| 166 |
PCV8 TOTAL HEALTH CARE COSTS OF PATIENTS WITH CHRONIC NON-VALVULAR ATRIAL FIBRILLATION BEFORE AND AFTER TIA, ISCHEMIC STROKE OR MAJOR BLEED
|
Stephenson, JJ
|
|
2005
|
8 |
3 |
p. 263-
1 p.
|
artikel
|
| 167 |
PCV19 TRENDS IN PHARMACY USE AMONG VETERANS WITH CHRONIC HEART FAILURE (1999-2002)
|
Johnson, ML
|
|
2005
|
8 |
3 |
p. 266-
1 p.
|
artikel
|
| 168 |
PCV47 USE OF ANTIHYPERTENSIVE MEDICATIONS AMONG VETERANS NEWLY DIAGNOSED WITH HYPERTENSION
|
Vincze, G
|
|
2005
|
8 |
3 |
p. 275-
1 p.
|
artikel
|
| 169 |
PCV18 USE OF β-BLOCKERS FOR TREATING HEART FAILURE AMONG THE ELDERLY IN BRITISH COLUMBIA, CANADA, 1993-2001
|
Levy, A
|
|
2005
|
8 |
3 |
p. 266-
1 p.
|
artikel
|
| 170 |
PCV46 USE OF NON-US SUPPLIED PHARMACEUTICALS IN THE TREATMENT OF HYPERTENSION IN A LATINO POPULATION IN LOS ANGELES COUNTY, CA, USA
|
Wang, SM
|
|
2005
|
8 |
3 |
p. 274-275
2 p.
|
artikel
|
| 171 |
PCV3 UTILIZATION OF RECOMMENDED DRUG THERAPY IN ACUTE CORONARY SYNDROME
|
Patel, CK
|
|
2005
|
8 |
3 |
p. 261-
1 p.
|
artikel
|
| 172 |
PCV50 VENOUS THROMBOEMBOLISM PROPHYLAXIS AND DRUG USE VALUE OF ENOXAPARIN IN HOSPITALIZED MYOCARDIAL INFARCTION PATIENTS
|
Balu, S
|
|
2005
|
8 |
3 |
p. 276-
1 p.
|
artikel
|
| 173 |
PCV24 WHAT IS THE RELEVANCE OF AGE GROUPS IN SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS? A COST—UTILITY ANALYSIS IN MEXICO
|
Mould Quevedo, JF
|
|
2005
|
8 |
3 |
p. 268-
1 p.
|
artikel
|
| 174 |
PDB28 AN EVALUATION OF A DISEASE MANAGEMENT PROGRAM FOR ADULT DIABETICS IN A MEDICAID POPULATION
|
Yaffe, K
|
|
2005
|
8 |
3 |
p. 360-361
2 p.
|
artikel
|
| 175 |
PDB43 ASSOCIATIONS AMONG VISUAL IMPAIRMENT, STAGE OF DIABETIC RETINOPATHY AND QUALITY OF LIFE (EQ-5D)
|
Smith, D
|
|
2005
|
8 |
3 |
p. 365-
1 p.
|
artikel
|
| 176 |
PDB17 BURDEN OF ILLNESS ASSOCIATED WITH SYMPTOMS OF DIABETIC PERIPHERAL NEUROPATHY AND DIABETIC RETINOPATHY
|
Candrilli, SD
|
|
2005
|
8 |
3 |
p. 357-
1 p.
|
artikel
|
| 177 |
PDB26 BURDEN OF NON-ADHERENCE TO ORAL ANTIDIABETICS
|
Curkendall, S
|
|
2005
|
8 |
3 |
p. 360-
1 p.
|
artikel
|
| 178 |
PDB5 CAN USE OF GLITAZONES REDUCE THE RISK OF ALZHEIMER'S DISEASE IN PATIENTS WITH DIABETES?
|
Yu, AP
|
|
2005
|
8 |
3 |
p. 353-
1 p.
|
artikel
|
| 179 |
PDB7 CLINICAL JUDGMENT OF DRUG THERAPY FOR TYPE-2 DIABETES PATIENTS AND RESULTS OF HBA1C TESTS
|
Lipskiy, N
|
|
2005
|
8 |
3 |
p. 354-
1 p.
|
artikel
|
| 180 |
PDB19 COLLECTION OF COST DATA FOR DIABETES COMPLICATIONS IN CANADA AND AUSTRALIA
|
Palmer, AJ
|
|
2005
|
8 |
3 |
p. 357-358
2 p.
|
artikel
|
| 181 |
PDB20 COMPARISON OF THE COST TO REACH A1C TARGETS IN PATIENTS WITH TYPE-2 DIABETES MELLITUS ON ORAL ANTIDIABETIC AGENTS AND EITHER BIPHASIC INSULIN ASPART 70/30 OR INSULIN GLARGINE
|
Cobden, D
|
|
2005
|
8 |
3 |
p. 358-
1 p.
|
artikel
|
| 182 |
PDB13 COST OF DIABETES COMPLICATIONS IN FRANCE, GERMANY, ITALY AND SPAIN
|
Palmer, AJ
|
|
2005
|
8 |
3 |
p. 355-356
2 p.
|
artikel
|
| 183 |
PDB25 DEPRESSION IN PATIENTS WITH TYPE-2 DIABETES: IMPACT ON UTILIZATION PATTERNS AND ADHERENCE TO ORAL HYPOGLYCEMIC AGENTS
|
Kalsekar, I
|
|
2005
|
8 |
3 |
p. 359-360
2 p.
|
artikel
|
| 184 |
PDB39 DEVELOPMENT OF AN INTEGRATED DIABETES DATABASE ACROSS COMMUNITY CLINICS AND HOSPITALS
|
Ho, MJ
|
|
2005
|
8 |
3 |
p. 364-
1 p.
|
artikel
|
| 185 |
PDB15 DIABETIC RETINOPATHY MODELING:A COST-EFFECTIVENESS OF VARYING SCREENING INTERVALS IN TYPE-2 DIABETES MELLITUS IN THAILAND
|
Pornpinatepong, S
|
|
2005
|
8 |
3 |
p. 356-
1 p.
|
artikel
|
| 186 |
PDB3 EARLY DETECTION OF CVD BY MYOCARDIAL PERFUSION IMAGING IN ASYMPTOMATIC PATIENTS WITH DIABETES
|
Papatheofanis, FJ
|
|
2005
|
8 |
3 |
p. 352-353
2 p.
|
artikel
|
| 187 |
PDB10 ECONOMIC BURDEN OF DIABETIC RETINOPATHY IN FLORIDA: A PILOT STUDY EXPLORING THE AMOUNT SPENT USING PRINCIPLE DIAGNOSES
|
Batiste, L
|
|
2005
|
8 |
3 |
p. 355-
1 p.
|
artikel
|
| 188 |
PDB14 ECONOMIC EVALUATION OF DETEMIR-BASED BASAL/BOLUS THERAPY VERSUS NEUTRAL PROTAMINE HAGEDORN-BASED BASAL/BOLUS THERAPY FOR TYPE-1 DIABETES IN A DUTCH SETTING
|
Roze, S
|
|
2005
|
8 |
3 |
p. 356-
1 p.
|
artikel
|
| 189 |
PDB18 ECONOMIC EVALUATION OF DRUG THERAPY AMONG DIABETES MILLITUS PATIENTS IN OLABISI ONABANJO UNIVERSITY TEACHING HOSPITAL, SAGAMU, OGUN
|
Suleiman, IA
|
|
2005
|
8 |
3 |
p. 357-
1 p.
|
artikel
|
| 190 |
PDB24 ECONOMIC IMPACT OF CARDIOVASCULAR CO-MORBIDITY IN PATIENTS WITH TYPE-2 DIABETES
|
Mody, R
|
|
2005
|
8 |
3 |
p. 359-
1 p.
|
artikel
|
| 191 |
PDB12 EFFECT OF GLYCEMIC CONTROL ON HEALTH CARE COSTS
|
Secnik, K
|
|
2005
|
8 |
3 |
p. 355-
1 p.
|
artikel
|
| 192 |
PDB42 ESTIMATING THE EFFECT OF SYMPTOMS OF DIABETIC PERIPHERAL NEUROPATHY AND DIABETIC RETINOPATHY ON QUALITY-OF-LIFE USING DATA FROM THE 2001–2002 NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY
|
Davis, KL
|
|
2005
|
8 |
3 |
p. 365-
1 p.
|
artikel
|
| 193 |
PDB11 EVALUATION OF THE CLINICAL OUTCOME AND FINANCIAL COSTS OF DELAYING THE ONSET OF FRANK TYPE-2 DIABETES
|
McEwan, P
|
|
2005
|
8 |
3 |
p. 355-
1 p.
|
artikel
|
| 194 |
PDB23 EVALUATION OF THE IMPACT ON THE EQ5DINDEX (HEATH-RELATED UTILITY) OF CONVERSION TO INSULIN GLARGINE (LANTUS) FOLLOWING FAILURE ON ORAL AGENTS IN PEOPLE WITH TYPE-2 DIABETES: INTERIM ANALYSIS
|
Peters, JR
|
|
2005
|
8 |
3 |
p. 359-
1 p.
|
artikel
|
| 195 |
PDB35 FACTOR ANALYSIS AND PRELIMINARY VALIDATION OF INSULIN DELIVERY SYSTEM QUESTIONNAIRE
|
Hayes, RP
|
|
2005
|
8 |
3 |
p. 362-363
2 p.
|
artikel
|
| 196 |
PDB9 FACTORS ASSOCIATED WITH A LOWER GLYCOSYLATED HEMOGLOBIN A1C (A1C) IN A DIABETIC LATINO POPULATION
|
Aranda, GA
|
|
2005
|
8 |
3 |
p. 354-355
2 p.
|
artikel
|
| 197 |
PDB31 FACTORS ASSOCIATED WITH HEALTH CARE COST SAVING IN PATIENTS WITH DIABETES TO THE CALIFORNIA MEDICAID POPULATIONS (MEDI-CAL)
|
Chaikledkaew, U
|
|
2005
|
8 |
3 |
p. 361-
1 p.
|
artikel
|
| 198 |
PDB4 GLYCEMIC RESPONSE TO PIOGLITAZONE THERAPY IN AFRICAN-AMERICAN AND LATINO PATIENTS WITH TYPE-2 DIABETES
|
Rajagopalan, R
|
|
2005
|
8 |
3 |
p. 353-
1 p.
|
artikel
|
| 199 |
PDB21 HEALTH CARE RESOURCE UTILIZATION AND COST IN TYPE-2 DIABETES PATIENTS RECEIVING COMBINATION SULFONYLUREA (SU) AND ROSIGLITAZONE (RSG): THE RESULT TRIAL
|
Herman, WH
|
|
2005
|
8 |
3 |
p. 358-
1 p.
|
artikel
|
| 200 |
PDB37 HEALTH ECONOMIC COMPARISON OF INSULIN ASPART, A FAST-ACTING INSULIN ANALOG, VERSUS HUMAN INSULIN AS MEALTIME INSULIN IN THE TREATMENT OF TYPE-1 DIABETES IN AUSTRIAN, DANISH, DUTCH, FINNISH, FRENCH, GERMAN, NORWEGIAN, SPANISH AND SWEDISH SETTINGS
|
Palmer, AJ
|
|
2005
|
8 |
3 |
p. 363-
1 p.
|
artikel
|
| 201 |
PDB27 IMPACT OF A DIABETES CARE PROJECT ON MEDICATION UTILIZATION AND ADHERENCE
|
Lee, K
|
|
2005
|
8 |
3 |
p. 360-
1 p.
|
artikel
|
| 202 |
PDB2 IMPACT OF DEPRESSION ON INCIDENCE OF TYPE-2 DIABETES IN A STATE MEDICAID POPULATION
|
Kalsekar, I
|
|
2005
|
8 |
3 |
p. 352-
1 p.
|
artikel
|
| 203 |
PDB44 IS DIABETES KNOWLEDGE ASSOCIATED WITH HEALTH-RELATED QUALITY OF LIFE AMONG ENGLISH-SPEAKING SUBJECTS WITH DIABETES IN SINGAPORE?
|
Zhang, XH
|
|
2005
|
8 |
3 |
p. 365-366
2 p.
|
artikel
|
| 204 |
PDB22 LONG-TERM COST-EFFECTIVENESS OF INSULIN ASPART VERSUS SOLUBLE HUMAN INSULIN IN PATIENTS WITH TYPE 1 DIABETES IN THE UNITED KINGDOM
|
Minshall, ME
|
|
2005
|
8 |
3 |
p. 358-359
2 p.
|
artikel
|
| 205 |
PDB38 MEASURING THE EFFECT OF THE VARIABILITY OF INSULIN USE ON HEALTH CARE COSTS IN DIABETES
|
Curkendall, S
|
|
2005
|
8 |
3 |
p. 363-364
2 p.
|
artikel
|
| 206 |
PDB34 NEEDLESTICK INJURY IN NURSES CARING FOR PATIENTS WITH DIABETES
|
Pashos, CL
|
|
2005
|
8 |
3 |
p. 362-
1 p.
|
artikel
|
| 207 |
PDB33 PRESCRIBING TRENDS FOR COMBINATION PRODUCTS IN THE TREATMENT OF TYPE-II DIABETES
|
Bilek, JC
|
|
2005
|
8 |
3 |
p. 362-
1 p.
|
artikel
|
| 208 |
PDB1 PREVALENCE OF CO-MORBID CONDITIONS AND CONCOMITANT MEDICATION USE AMONG TYPE-2 DIABETES PATIENTS IN A STATE MEDICAID POPULATION
|
Kavookjian, J
|
|
2005
|
8 |
3 |
p. 352-
1 p.
|
artikel
|
| 209 |
PDB8 PREVALENCE OF DIABETES MELLITUS AND TREATMENT PATTERNS BASED ON CLASSIFICATION OF BODY MASS INDEX AMONG ADULTS
|
Suh, DC
|
|
2005
|
8 |
3 |
p. 354-
1 p.
|
artikel
|
| 210 |
PDB45 QUALITY OF LIFE (SF12), CLINICAL OUTCOMES, AND COMORBID CONDITIONS IN PATIENTS WITH TYPE-2 DIABETES: A POPULATION STUDY
|
Sundaram, M
|
|
2005
|
8 |
3 |
p. 366-
1 p.
|
artikel
|
| 211 |
PDB36 RELIABILITY AND VALIDITY OF THE GENERAL DIABETES KNOWLEDGE TEST
|
Wee, HL
|
|
2005
|
8 |
3 |
p. 363-
1 p.
|
artikel
|
| 212 |
PDB16 THE ASSOCIATION BETWEEN DIABETES RELATED MEDICAL COSTS AND GLYCEMIC CONTROL: A LONGITUDINAL ANALYSIS
|
Oglesby, A
|
|
2005
|
8 |
3 |
p. 356-357
2 p.
|
artikel
|
| 213 |
PDB29 THE EFFECT OF INSULIN TREATMENT ON HEALTH CARE UTILIZATION IN TYPE-II DIABETES
|
Thiebaud, P
|
|
2005
|
8 |
3 |
p. 361-
1 p.
|
artikel
|
| 214 |
PDB32 THE RELATIONSHIP BETWEEN PATIENT'S TYPE OF PAYMENT AND PRESCRIPTION DRUG COSTS FOR DIABETIC PATIENTS
|
Ngorsuraches, S
|
|
2005
|
8 |
3 |
p. 361-362
2 p.
|
artikel
|
| 215 |
PDB40 THE USE OF DIABETES PREVENTION PROGRAM RESULTS TO MODEL COST-EFFECTIVENESS OF THE INTERVENTION IN A MORE GENERALIZED HYPOTHETICAL POPULATION
|
Novak, S
|
|
2005
|
8 |
3 |
p. 364-
1 p.
|
artikel
|
| 216 |
PDB30 TREATMENT PATTERNS AMONG PATIENTS WITH DIABETES ON METFORMIN AND SULFONYLUREA COMBINATION THERAPY
|
Pietri, G
|
|
2005
|
8 |
3 |
p. 361-
1 p.
|
artikel
|
| 217 |
PDB6 TREATMENT PATTERNS IN MANAGEMENT OF TYPE-2 DIABETES WITH CONCURRING COMORBIDITIES
|
Lipskiy, N
|
|
2005
|
8 |
3 |
p. 353-354
2 p.
|
artikel
|
| 218 |
PDB41 VALIDATION OF THE GERMAN TRANSLATION OF THE NORFOLK QOL-DN, NERVE FIBER SPECIFIC QUESTIONNAIRE
|
Vinik, EJ
|
|
2005
|
8 |
3 |
p. 364-365
2 p.
|
artikel
|
| 219 |
PDB46 WILLINGNESS-TO-PAY FOR INHALED INSULIN—A CANADIAN PERSPECTIVE
|
Sadri, H
|
|
2005
|
8 |
3 |
p. 366-
1 p.
|
artikel
|
| 220 |
PEN1 COST SAVINGS ASSOCIATED WITH FINER DOSING INCREMENTS THROUGH THE USE OF NORDITROPIN NORDIFLEX® IN THE UNITED STATES
|
Joshi, AV
|
|
2005
|
8 |
3 |
p. 279-
1 p.
|
artikel
|
| 221 |
PEN2 COST-UTILITY OF NORDITROPIN® (R-DNA SOMATROPIN) IN CHILDREN WITH GROWTH HORMONE DEFICIENCY
|
Joshi, AV
|
|
2005
|
8 |
3 |
p. 279-
1 p.
|
artikel
|
| 222 |
PEN5 ESTIMATING THE QUALITY OF LIFE DEFICIT IN ADULT GROWTH HORMONE DEFICIENCY USING AN EQ-5D CALIBRATED INDEX
|
Kind, P
|
|
2005
|
8 |
3 |
p. 280-
1 p.
|
artikel
|
| 223 |
PEN6 EVALUATION OF THE ASSOCIATION BETWEEN HEIGHT AND HEALTH-RELATED UTILITY (EQ5DINDEX)
|
Woehl, A
|
|
2005
|
8 |
3 |
p. 280-281
2 p.
|
artikel
|
| 224 |
PEN4 GENERIC AND DISEASE—SENSITIVE INSTRUMENTS SEEM TO MEASURE QUALITY OF LIFE IN A SIMILAR WAY: RESULTS OF THE EQ-5D AND QOL-AGHDA SURVEY IN THE SWEDISH POPULATION
|
Koltowska-Haggstrom, M
|
|
2005
|
8 |
3 |
p. 280-
1 p.
|
artikel
|
| 225 |
PEN3 HEALTH STATUS VALUES (UTILITIES) FOR THE SWEDISH POPULATION: A MODEL BASED ON THE EQ-5D ASSESSMENT OF ACTUAL HEALTH STATE, USING JACKKNIFE METHOD AND MULTIPLE REGRESSION ANALYSIS
|
Jonsson, B
|
|
2005
|
8 |
3 |
p. 279-280
2 p.
|
artikel
|
| 226 |
PER1 EVALUATION OF AN OTITIS MEDIA EDUCATION INTERVENTION IN AN INTEGRATED DELIVERY SYSTEM
|
Beaton, SJ
|
|
2005
|
8 |
3 |
p. 366-367
2 p.
|
artikel
|
| 227 |
PER2 PROCESS EVALUATION OF THE IMPLEMENTATION OF OTITIS MEDIA GUIDELINES IN AN INTEGRATED DELIVERY SYSTEM
|
Gunter, MJ
|
|
2005
|
8 |
3 |
p. 367-
1 p.
|
artikel
|
| 228 |
PEY4 A COST-BENEFIT ANALYSIS OF AN APODIZED DIFFRACTIVE MULTIFOCAL INTRA-OCULAR LENS BASED ON WILLINGNESS-TO-PAY IN CATARACT PATIENTS
|
Waycaster, C
|
|
2005
|
8 |
3 |
p. 368-
1 p.
|
artikel
|
| 229 |
PEY2 CHARACTERIZATION OF THE FREQUENCY AND REASONS FOR CHANGES IN PHARMACOTHERAPY IN THE TREATMENT OF PRIMARY OPEN-ANGLE GLAUCOMA, NORMAL TENSION GLAUCOMA, AND OCULAR HYPERTENSION USING RETROSPECTIVE ANALYSIS OF THE GLASGOW ROYAL INFIRMARY GLAUCOMA DATABASE
|
Montgomery, D
|
|
2005
|
8 |
3 |
p. 367-368
2 p.
|
artikel
|
| 230 |
PEY1 COMORBIDITIES AND INCIDENCE RATE OF GLAUCOMA IN THE CALIFORNIA MEDICAID POPULATION—A CASE-CONTROL STUDY
|
Lee, LJ
|
|
2005
|
8 |
3 |
p. 367-
1 p.
|
artikel
|
| 231 |
PEY7 COST OF GLAUCOMA TO THE CALIFORNIA MEDICAID (MEDI-CAL) PROGRAM BETWEEN 1995 AND 2002
|
Lee, LJ
|
|
2005
|
8 |
3 |
p. 369-
1 p.
|
artikel
|
| 232 |
PEY6 MEDICAL CARE COSTS OF PRIMARY OPEN-ANGLE GLAUCOMA IN THE UNITED STATES:A NATIONAL ESTIMATE USING THE MEDICAL EXPENDITURE PANEL SURVEY
|
Mychaskiw, MA
|
|
2005
|
8 |
3 |
p. 369-
1 p.
|
artikel
|
| 233 |
PEY8 PATIENT-REPORTED VISUAL FUNCTION IN LOW-VISION POPULATIONS (NEI-VFQ):AN ANALYSIS WITH COMPARISONS OF READING PERFORMANCE, CONTRAST SENSITIVITY, SCOTOMA TESTING, AND VISUAL ACUITY
|
Tencer, T
|
|
2005
|
8 |
3 |
p. 369-
1 p.
|
artikel
|
| 234 |
PEY3 REFILL COSTS AND BUDGET IMPACT OF GLAUCOMA LIPID THERAPY: A RETROSPECTIVE DATABASE ANALYSIS
|
Walt, JG
|
|
2005
|
8 |
3 |
p. 368-
1 p.
|
artikel
|
| 235 |
PEY5 THE COST-EFFECTIVENESS OF DIFFERENT CASE-FINDING STRATEGIES FOR DETECTION AND TREATMENT OF OCULAR HYPERTENSION AND PRIMARY OPEN-ANGLE GLAUCOMA BY THE OPHTHALMOLOGIST
|
Peeters, A
|
|
2005
|
8 |
3 |
p. 368-
1 p.
|
artikel
|
| 236 |
PGI12 COMPARISON OF THE MEDICATION POSSESSION RATIO ALONE AND IN COMBINATION WITH BREAKTHROUGH EVENTS FOR CLASSIFYING PATIENTS WITH ACID RELATED DISEASES
|
Brook, RA
|
|
2005
|
8 |
3 |
p. 373-
1 p.
|
artikel
|
| 237 |
PGI5 COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) COMPARED TO LAMIVUDINE FOR THE TREATMENT OF E ANTIGEN NEGATIVE CHRONIC HEPATITIS B IN THE UK
|
Veenstra, DL
|
|
2005
|
8 |
3 |
p. 371-
1 p.
|
artikel
|
| 238 |
PGI14 DOES A CLINICAL STUDY REFLECT REAL-LIFE AND REAL-LIFE COSTS
|
Juhl, HH
|
|
2005
|
8 |
3 |
p. 373-374
2 p.
|
artikel
|
| 239 |
PGI8 EVALUATION OF OTC PRILOSEC STEP CARE PROGRAMS ON THE UTILIZATION AND COSTS OF PROTON PUMP INHIBITORS
|
Sun, SX
|
|
2005
|
8 |
3 |
p. 372-
1 p.
|
artikel
|
| 240 |
PGI16 HEALTH RELATED QUALITY OF LIFE CHANGES IN LAMIVUDINE REFRACTORY CHRONIC HEPATITIS B (CHB PATIENTS AFTER ENTECAVIR (ETV) OR LAMIVUDINE (LAM) TREATMENT¡V BMS STUDY 026
|
Su, J
|
|
2005
|
8 |
3 |
p. 374-
1 p.
|
artikel
|
| 241 |
PGI10 IS THE INTRODUCTION OF REFERENCE BASED PRICING FOR PATENT PROTECTED DRUGS A COST-SAVING OPTION FOR HEALTH CARE?
|
Kulp, W
|
|
2005
|
8 |
3 |
p. 372-
1 p.
|
artikel
|
| 242 |
PGI11 LINKING SYMPTOMS SEVERITY AND DIURNALITY TO PRODUCTIVITY LOSS-A NEW CONCEPTUAL APPROACH
|
Nordyke, RJ
|
|
2005
|
8 |
3 |
p. 372-373
2 p.
|
artikel
|
| 243 |
PGI7 MANAGING CROHN'S DISEASE: USE AND COST OF INPATIENT, EMERGENCY DEPARTMENT AND OBSERVATION
|
O'Brien, J
|
|
2005
|
8 |
3 |
p. 371-372
2 p.
|
artikel
|
| 244 |
PGI9 MODELING RISK OF GI EVENTS AMONG MEDICAID NSAID USERS, USING PROPENSITY SCORES
|
Shaya, FT
|
|
2005
|
8 |
3 |
p. 372-
1 p.
|
artikel
|
| 245 |
PGI1 PREVALENCE AND RISK FACTORS FOR DIARRHEA AT A LARGE TERTIARY CARE MEDICAL CENTER
|
Kachroo, S
|
|
2005
|
8 |
3 |
p. 369-370
2 p.
|
artikel
|
| 246 |
PGI17 TEGASEROD SIGNIFICANTLY IMPROVES QUALITY OF LIFE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)
|
Minguez, M
|
|
2005
|
8 |
3 |
p. 374-375
2 p.
|
artikel
|
| 247 |
PGI2 THE BUDGET IMPACT OF TEGASEROD ON A MANAGED CARE ORGANIZATION FORMULARY
|
Bloom, MA
|
|
2005
|
8 |
3 |
p. 370-
1 p.
|
artikel
|
| 248 |
PGI4 THE COST-EFFECTIVENESS OF TWO STRATEGIES FOR VACCINATING PATIENTS WITH HEPATITIS C VIRUS INFECTION AGAINST HEPATITIS A AND HEPATITIS B
|
Borrego, ME
|
|
2005
|
8 |
3 |
p. 370-371
2 p.
|
artikel
|
| 249 |
PGI3 THE ECONOMIC IMPLICATIONS OF SOMATROPIN [RDNA ORIGIN] MANAGEMENT IN PATIENTS WITH SHORT BOWEL SYNDROME
|
Migliaccio-Walle, K
|
|
2005
|
8 |
3 |
p. 370-
1 p.
|
artikel
|
| 250 |
PGI13 USING ADVANCED SIMULATION MODELING TO EXAMINE THE IMPACT OF INCREASED RESOURCES ON PATIENT THROUGHPUT IN OUTPATIENT CARE
|
Lahue, BJ
|
|
2005
|
8 |
3 |
p. 373-
1 p.
|
artikel
|
| 251 |
PGI6 UTILIZATION, RE-TREATMENT, AND COST OF DIFFERING LENGTHS OF H. PYLORI TREATMENT REGIMENS FROM US HEALTH CARE CLAIMS DATABASES
|
Orsini, LS
|
|
2005
|
8 |
3 |
p. 371-
1 p.
|
artikel
|
| 252 |
PGI15 VALIDATION OF EDC VERSIONS OF IBS-QOL, EQ-5D AND WPAI-IBS QUESTIONNAIRES
|
Bushnell, DM
|
|
2005
|
8 |
3 |
p. 374-
1 p.
|
artikel
|
| 253 |
PHM6 A HIDDEN EPIDEMIC AMONG ACUTE CARE INPATIENTS: ECONOMIC AND CLINICAL IMPACTS OF ANEMIA IN SELECTED CHRONIC DISEASES
|
Wang, PF
|
|
2005
|
8 |
3 |
p. 282-
1 p.
|
artikel
|
| 254 |
PHM4 COST-EFFECTIVENESS OF TRANSFUSING BLOOD PLATELETS PREPARED WITH PATHOGEN INACTIVATION TREATMENT IN CHINA
|
Staginnus, U
|
|
2005
|
8 |
3 |
p. 282-
1 p.
|
artikel
|
| 255 |
PHM3 DOES ANEMIA CONTRIBUTE TO LONGER LENGTH OF STAY IN PATIENTS WITH IN-HOSPITAL FALLS?
|
Mallik, AV
|
|
2005
|
8 |
3 |
p. 281-
1 p.
|
artikel
|
| 256 |
PHM1 EFFECTIVENESS OF EPOETIN ALFA IN REDUCING THE NUMBER OF BLOOD TRANSFUSIONS IN CRITICALLY ILL SICU PATIENTS
|
Luh, VW
|
|
2005
|
8 |
3 |
p. 281-
1 p.
|
artikel
|
| 257 |
PHM2 IMPACT OF ANEMIA ON IN-HOSPITAL FALLS: A MATCHED CASE-CONTROL STUDY
|
Mallik, AV
|
|
2005
|
8 |
3 |
p. 281-
1 p.
|
artikel
|
| 258 |
PHM5 RECOMBINANT HUMAN FACTOR VII USE: AN EVALUATION OF PATIENT CHARACTERISTICS AND OUTCOMES FROM AN ELECTRONIC DATABASE OF ACADEMIC HEALTH CENTERS
|
Magnetti, S
|
|
2005
|
8 |
3 |
p. 282-
1 p.
|
artikel
|
| 259 |
PHP38 A CENTRAL COMPUTERIZED DRUG PRIOR-AUTHORIZATION PROCESS IN A MANAGED CARE SETTING IN ISRAEL
|
Kahan, NR
|
|
2005
|
8 |
3 |
p. 294-
1 p.
|
artikel
|
| 260 |
PHP25 ANALYSIS OF PRESCRIBING PATTERN WITH THE NEGATIVE LIST FORMULARY SYSTEM IN KOREA
|
Lee, EK
|
|
2005
|
8 |
3 |
p. 290-
1 p.
|
artikel
|
| 261 |
PHP29 AN ANALYSIS OF PUBLICATION RATES OF ABSTRACTS PRESENTED AT THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICSAND OUTCOMES RESEARCH (ISPOR) INTERNATIONALAND EUROPEAN CONFERENCES DURING YEARS 2000 THROUGH 2003
|
Vo, PG
|
|
2005
|
8 |
3 |
p. 291-
1 p.
|
artikel
|
| 262 |
PHP34 AN ASSESSMENT OF THE ASSOCIATION BETWEEN UNDERLYING WORKER MEDICAL CONDITIONS AND WORKER ABSENTEEISM IN THE US
|
Mavros, P
|
|
2005
|
8 |
3 |
p. 292-293
2 p.
|
artikel
|
| 263 |
PHP42 AN EXPLORATION OF PATIENT FACTORS INFLUENCING PRESCRIBERACTIVITY IN UK GENERAL PRACTICE
|
Richard, LJ
|
|
2005
|
8 |
3 |
p. 295-
1 p.
|
artikel
|
| 264 |
PHP49 BRIEF SUMMARY FORMATS OF DTCATO IMPROVE CONSUMER COMPREHENSION
|
Sansgiry, SS
|
|
2005
|
8 |
3 |
p. 297-
1 p.
|
artikel
|
| 265 |
PHP1 COST EFFECTIVENESS OF INTERVENTIONS TO IMPROVE ADHERENCE: WHAT IS THE QUALITY OF THE EVIDENCE?
|
Elliott, RA
|
|
2005
|
8 |
3 |
p. 282-283
2 p.
|
artikel
|
| 266 |
PHP47 COST-MINIMIZATION ANALYSIS OF SEROLOGIC SCREENING POLICY OPTIONS FOR US ARMY ACCESSION IMMUNIZATIONS
|
Nevin, RL
|
|
2005
|
8 |
3 |
p. 297-
1 p.
|
artikel
|
| 267 |
PHP40 DEVELOPING KEY PERFORMANCE INDICATORS FORTHE AUSTRALIAN REIMBURSEMENT SYSTEM
|
Abela, M
|
|
2005
|
8 |
3 |
p. 294-295
2 p.
|
artikel
|
| 268 |
PHP39 DEVELOPMENT AND VALIDATION OF A CLAIMS-BASED RISK ASSESSMENT MODEL TO PREDICT PHARMACY EXPENDITURES IN A COMMERCIAL POPULATION
|
Cantrell, CR
|
|
2005
|
8 |
3 |
p. 294-
1 p.
|
artikel
|
| 269 |
PHP20 EFFECT OF A PHARMACY BENEFIT CHANGE ON ACCURACY OF PRESCRIPTION DATABASE'S DAYS SUPPLYVARIABLE
|
Smith, K
|
|
2005
|
8 |
3 |
p. 288-
1 p.
|
artikel
|
| 270 |
PHP37 EVALUATING PHARMACEUTICALS FOR REIMBURSEMENT IN KOREA
|
Choi, SE
|
|
2005
|
8 |
3 |
p. 293-294
2 p.
|
artikel
|
| 271 |
PHP45 EVALUATING THE EFFECTIVENESS OF A PROTOCOL FOR SEDATION OF MECHANICALLYVENTILATED PATIENTS IN AN ACUTE CARE SETTING
|
Basskin, LE
|
|
2005
|
8 |
3 |
p. 296-
1 p.
|
artikel
|
| 272 |
PHP8 EVALUATION OF A CLINICAL PHARMACOKINETIC MONITORING SYSTEM
|
Chan, YY
|
|
2005
|
8 |
3 |
p. 285-
1 p.
|
artikel
|
| 273 |
PHP9 EVALUATION OF A PLAN-PARTICIPANT MAILING PROGRAM TO ENCOURAGE USE OF MAIL-SERVICE PHARMACY AND FORMULARY DRUGS
|
Powers, CA
|
|
2005
|
8 |
3 |
p. 285-
1 p.
|
artikel
|
| 274 |
PHP36 EXAMINING THE QUALITY OF HEALTH ECONOMIC ANALYSES SUBMITTED TO THE PHARMACEUTICAL BENEFITS BOARD IN SWEDEN.—DATA FROM THE FIRST TWO YEARS
|
Odeberg, S
|
|
2005
|
8 |
3 |
p. 293-
1 p.
|
artikel
|
| 275 |
PHP43 FACTORS THAT INFLUENCE PRESCRIBING OF LOW-MOLECULAR-WEIGHT HEPARINS
|
Blackburn, J
|
|
2005
|
8 |
3 |
p. 295-296
2 p.
|
artikel
|
| 276 |
PHP23 FINANCING TO MEDICINES IN MEXICO
|
Molina, R
|
|
2005
|
8 |
3 |
p. 289-
1 p.
|
artikel
|
| 277 |
PHPI6 ADVERTISING IN RESPONSE TO NEW PRODUCT ENTRY: AN EXAMINATION OF THE STRATEGIC ROLE OF PHARMACEUTICAL ADVERTISING ON MARKET COMPETITION
|
Kwong, WJ
|
|
2005
|
8 |
3 |
p. 287-
1 p.
|
artikel
|
| 278 |
PHP4I A PRELIMINARY ANALYSIS OF THE RELATIONSHIP BETWEEN CONSULTATION LENGTH AND PRESCRIBER ACTIVITY IN UK GENERAL PRACTICE
|
Richard, LJ
|
|
2005
|
8 |
3 |
p. 295-
1 p.
|
artikel
|
| 279 |
PHPII IMPACT OF A 90-DAY RETAIL PROGRAM ON PRESCRIPTION DRUG EXPENDITURES
|
Sun, SX
|
|
2005
|
8 |
3 |
p. 286-
1 p.
|
artikel
|
| 280 |
PHPI4 MAKING A CASE FOR EMPLOYING SOCIETAL PERSPECTIVE IN THE EVALUATION OF MEDICAID FORMULARIES
|
Roy, S
|
|
2005
|
8 |
3 |
p. 286-287
2 p.
|
artikel
|
| 281 |
PHPI9 MEDICATION NEEDS OF ELDERLY INDIVIDUALS WITHOUT PRESCRIPTION DRUG COVERAGE
|
Tran, BV
|
|
2005
|
8 |
3 |
p. 288-
1 p.
|
artikel
|
| 282 |
PHPI7 MODELING THE COST AND UTILIZATION OF MAIL ORDER VS. COMMUNITY PHARMACY IN A MEDICAID POPULATION
|
Valluri, SC
|
|
2005
|
8 |
3 |
p. 287-288
2 p.
|
artikel
|
| 283 |
PHP4 IMPACT OF COST ON MEDICATION COMPLIANCE IN PATIENTS WITH DIFFERENT LEVELS OF PERCEIVED BENEFITS
|
Fuldeore, M
|
|
2005
|
8 |
3 |
p. 283-284
2 p.
|
artikel
|
| 284 |
PHP22 IMPACT OF HEALTH INSURANCE ON HEALTH-RELATED QUALITY OF LIFE
|
Bharmal, M
|
|
2005
|
8 |
3 |
p. 289-
1 p.
|
artikel
|
| 285 |
PHP3 IMPACT OF INCREASED COPAYMENTS ON THE SWITCHING AND DISCONTINUATION RATES FOR NON FORMULARY MEDICATIONS
|
Nair, KV
|
|
2005
|
8 |
3 |
p. 283-
1 p.
|
artikel
|
| 286 |
PHP46 IMPACT OF PRESCRIBING GUIDELINES FOR INPATIENT ANTICOAGULATION
|
Blackburn, J
|
|
2005
|
8 |
3 |
p. 296-
1 p.
|
artikel
|
| 287 |
PHPI5 PHARMACOECONOMIC EDUCATION AT MEDICAL SCHOOLS IN TURKEY
|
Tulunay, F
|
|
2005
|
8 |
3 |
p. 287-
1 p.
|
artikel
|
| 288 |
PHP3I: SAFETY NET ACTIVITIES STRUCTURAL CHARACTERISTICS & MEMBERSHIP IN LOCAL HOSPITAL SYSTEMS
|
Khan, N
|
|
2005
|
8 |
3 |
p. 292-
1 p.
|
artikel
|
| 289 |
PHPI2 SOCIAL AND ECONOMIC FACTORS AFFECTING INTENTIONAL PRESCRIPTION DRUG NON-COMPLIANCE AMONG NOVA SCOTIA SENIORS
|
Okihiro, NR
|
|
2005
|
8 |
3 |
p. 286-
1 p.
|
artikel
|
| 290 |
PHP48 ISPOR PHARMACOECONOMICS & OUTCOMES RESEARCH ABSTRACTS: TRENDS & QUALITY INDICATORS
|
Smith, MD
|
|
2005
|
8 |
3 |
p. 297-
1 p.
|
artikel
|
| 291 |
PHPI8 THE INFLUENCE OF DRUG COPAY CHANGE ON DRUG UTILIZATION: THE CASE OF SMALL-FIRM EMPLOYEES IN CALIFORNIA
|
Thiebaud, P
|
|
2005
|
8 |
3 |
p. 288-
1 p.
|
artikel
|
| 292 |
PHP2I TRENDS IN PHARMACEUTICAL SPENDING GROWTH IN THE UNITED STATES, 1998-2002
|
Roberts, WM
|
|
2005
|
8 |
3 |
p. 289-
1 p.
|
artikel
|
| 293 |
PHPI3 TRENDS IN THE PREVALENCE OF INAPPROPRIATE PRESCRIBING AMONG ELDERLY MEDICARE BENEFICIARIES, 1992-2001
|
Mahmood, M
|
|
2005
|
8 |
3 |
p. 286-
1 p.
|
artikel
|
| 294 |
PHP35 OUTCOMES OF TECHNOLOGY APPLICATION ON PHARMACISTS JOB PERFORMANCE: THE ROLE OF PERSONAL DIGITAL ASSISTANTS
|
Sikri, S
|
|
2005
|
8 |
3 |
p. 293-
1 p.
|
artikel
|
| 295 |
PHP7 PRESCRIPTION DRUG NONCOMPLIANCE AMONG TRICARE BENEFICIARIES AT MILITARY PHARMACIES
|
Esposito, D
|
|
2005
|
8 |
3 |
p. 284-285
2 p.
|
artikel
|
| 296 |
PHP27 QUALITY OF ECONOMIC MODELS IN DOSSIERS SUBMITTED UNDERTHEAMCP FORMAT
|
Colmenero, F
|
|
2005
|
8 |
3 |
p. 290-291
2 p.
|
artikel
|
| 297 |
PHP6 SUMMARIZING DRUG USE OVER TIME: THE DRUG-O-GRAM
|
Gause, D
|
|
2005
|
8 |
3 |
p. 284-
1 p.
|
artikel
|
| 298 |
PHP26 THE CURRENT AND FUTURE OF PHARMACOECONOMICS IN UKRAINE
|
Zaliska, OM
|
|
2005
|
8 |
3 |
p. 290-
1 p.
|
artikel
|
| 299 |
PHP24 THE DETERMINANTS OF EXPENDITURES ON PHARMACEUTICALS AND OTHER MEDICAL NON-DURABLES IN OECD COUNTRIES
|
Zhang, D
|
|
2005
|
8 |
3 |
p. 289-290
2 p.
|
artikel
|
| 300 |
PHP28 THE EFFECT OF CORPORATE STRUCTURE ON FORMULARY DESIGN: THE CASE OF LARGE INSURANCE COMPANIES
|
Abrams, L
|
|
2005
|
8 |
3 |
p. 291-
1 p.
|
artikel
|
| 301 |
PHP2 THE MEDINET-PROJECT—A FEASIBILITY STUDY ON MEDICATION COMPLIANCE UNDER REAL LIFE CONDITIONS
|
Sterz, R
|
|
2005
|
8 |
3 |
p. 283-
1 p.
|
artikel
|
| 302 |
PHP5 TOOLS TO INCREASE THE APPROPRIATENESS OF ALBUMIN UTILIZATION IN AN ITALIAN COMMUNITY HOSPITAL
|
Panella, M
|
|
2005
|
8 |
3 |
p. 284-
1 p.
|
artikel
|
| 303 |
PHP32 TRENDSAND OUTCOMES ASSOCIATE WITH DTCA PRINT SUMMARY FORMATS: A FOURYEAR STUDY OF PRINT ADS
|
Sansgiry, SS
|
|
2005
|
8 |
3 |
p. 292-
1 p.
|
artikel
|
| 304 |
PHP30 USE OF EMERGENCY DEPARTMENTS BY HOMELESS PERSONS FOR NON-EMERGENCY CARE DURING ONEYEAR: RESOURCE USE AND COST
|
O'Brien, JA
|
|
2005
|
8 |
3 |
p. 291-292
2 p.
|
artikel
|
| 305 |
PHP44 USING THE TRANSTHEORETICAL MODEL (TTM) TO EXPLAIN, PREDICT OR INFLUENCE PHYSICIAN PATIENT CARE BEHAVIOR: A SYSTEMATIC REVIEW
|
Roy, AN
|
|
2005
|
8 |
3 |
p. 296-
1 p.
|
artikel
|
| 306 |
PHP33 UTILITY OF MEDIA ON HEALTH PROMOTION AND SELFMEDICATION
|
Tasic, D
|
|
2005
|
8 |
3 |
p. 292-
1 p.
|
artikel
|
| 307 |
PHP10 UTILIZATION AND COSTS OF A 90-DAY RETAIL PROGRAM IN COMPARISON WITH 30-DAY RETAIL AND MAIL SERVICES
|
Lee, K
|
|
2005
|
8 |
3 |
p. 285-
1 p.
|
artikel
|
| 308 |
PIH20 COST OF ILLNESS STUDY OF NAUSEA AND VOMITING OF PREGNANCY IN CANADA
|
Piwko, C
|
|
2005
|
8 |
3 |
p. 303-304
2 p.
|
artikel
|
| 309 |
PIH3 DIRECT COST OF TREATMENT FOR AUTISM SPECTRUM DISORDER IN CALIFORNIA MEDICAID
|
Flanders, S
|
|
2005
|
8 |
3 |
p. 298-
1 p.
|
artikel
|
| 310 |
PIH23 HEALTH PREFERENCES AND WILLINGNESS TO PAYTO REDUCE EXPOSURE TO POST-MENOPAUSAL RISK FACTORS
|
Szeinbach, SL
|
|
2005
|
8 |
3 |
p. 304-
1 p.
|
artikel
|
| 311 |
PIH2I ADJUSTMENT FOR PUBLICATION BIAS CHANGES THE APPARENT EFFICACY OF HORMONE TREATMENT-UNADJUSTED DATA MIGHT DISTORT THE RISK-BENEFIT TRADE OFF
|
Badamgarav, E
|
|
2005
|
8 |
3 |
p. 304-
1 p.
|
artikel
|
| 312 |
PIHI0 AN EXAMINATION OF SELF-REPORTED CHRONIC CONDITIONS AND HEALTH STATUS IN THE 2001 MEDICARE HEALTH OUTCOMES SURVEY
|
Ko, Y
|
|
2005
|
8 |
3 |
p. 300-301
2 p.
|
artikel
|
| 313 |
PIHI3 COST-EFFECTIVENESS ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) TREATMENTS
|
DiSantostefano, R
|
|
2005
|
8 |
3 |
p. 301-302
2 p.
|
artikel
|
| 314 |
PIHI9 COST-EFFECTIVENESS OF PHARMACIST PRESCRIBING AUTHORITY FOR EMERGENCY CONTRACEPTION IN BRITISH COLUMBIA
|
Soon, JA
|
|
2005
|
8 |
3 |
p. 303-
1 p.
|
artikel
|
| 315 |
PIHI8 DIRECT COSTS OF ERECTILE DYSFUNCTION IN A MANAGED CARE SETTING-EVIDENCE FROM A LARGE NATIONAL CLAIMS DATABASE
|
Sun, P
|
|
2005
|
8 |
3 |
p. 303-
1 p.
|
artikel
|
| 316 |
PIHI7 EVALUATION OF TADALAFIL AND VARDENAFIL TREATMENT PATTERNS IN PRIOR SILDENAFIL USERS
|
Harriett, J
|
|
2005
|
8 |
3 |
p. 302-303
2 p.
|
artikel
|
| 317 |
PIHI5 IMPACT OF BENEFIT DESIGN ON PDE-5 UTILIZATION AND COSTS IN A LARGE PBM DATABASE
|
Patel, BV
|
|
2005
|
8 |
3 |
p. 302-
1 p.
|
artikel
|
| 318 |
PIHI INCORPORATING OF HERD IMMUNITY INTO PHARMACOECONOMIC EVALUATION OF PNEUMOCOCCAL CONJUGATE VACCINE PNC-7
|
Claes, C
|
|
2005
|
8 |
3 |
p. 298-
1 p.
|
artikel
|
| 319 |
PIHII THE EFFECT OF OVER-THE-COUNTER DRUG MISUSE AND THE ASSOCIATED ADES ON HRQOL IN THE ELDERLY
|
Sansgiry, SS
|
|
2005
|
8 |
3 |
p. 301-
1 p.
|
artikel
|
| 320 |
PIH8 INAPPROPRIATE PRESCRIBING FOR ELDERLY PATIENTS IN TWO OUTPATIENT SETTINGS
|
Poston, S.
|
|
2005
|
8 |
3 |
p. 300-
1 p.
|
artikel
|
| 321 |
PIHI2 RELATIONSHIP BETWEEN QUALITY OF LIFE AND INAPPROPRIATE DRUG USE: A RETROSPECTIVE ANALYSIS IN AN ELDERLY POPULATION
|
Jiang, JZ
|
|
2005
|
8 |
3 |
p. 301-
1 p.
|
artikel
|
| 322 |
PIHI4 USE OF SILDENAFIL CITRATE IN NON-ADHERENT PATIENTS WITH CVD, DIABETES OR DEPRESSION
|
McLaughlin, T
|
|
2005
|
8 |
3 |
p. 302-
1 p.
|
artikel
|
| 323 |
PIHI6 UTILIZATION PATTERNS OF SIDENAFIL CITRATE IN A SENIOR MANAGED CARE POPULATION
|
Harriett, J
|
|
2005
|
8 |
3 |
p. 302-
1 p.
|
artikel
|
| 324 |
PIH9 MORAL HAZARD AND PRESCRIPTION DRUG USE AMONG NON-INSTITUTIONALIZED ELDERLY MEDICARE BENEFICIARIES
|
Gajria, KL
|
|
2005
|
8 |
3 |
p. 300-
1 p.
|
artikel
|
| 325 |
PIH22 NEW INSIGHTS INTO THE PLACEBO EFFECTS: A CASE STUDY OF THE EFFECTIVENESS OF HORMONE THERAPY ON THE FREQUENCY OF HOT FLASHES
|
Song, PJ
|
|
2005
|
8 |
3 |
p. 304-
1 p.
|
artikel
|
| 326 |
PIH6 TESTING FOR STREPTOCOCCAL INFECTIONS IN CHILDREN WITH PHARYNGITIS TREATED WITH ANTIBIOTICS INA LARGE ISRAELI HMO, 2003
|
Silverman, BG
|
|
2005
|
8 |
3 |
p. 299-
1 p.
|
artikel
|
| 327 |
PIH2 THE COST-EFFECTIVENESS OF EXPANDING NEWBORN SCREENING FOR INHERITED METABOLIC DISORDERS USING TANDEM MASS SPECTROMETRY
|
Cipriano, LE
|
|
2005
|
8 |
3 |
p. 298-
1 p.
|
artikel
|
| 328 |
PIH7 THE PREVALENCE OF POTENTIALLY INAPPROPRIATE MEDICATION USE IN THE ELDERLY
|
Jiang, JZ
|
|
2005
|
8 |
3 |
p. 299-300
2 p.
|
artikel
|
| 329 |
PIH4 THE QUALITY OF COMMUNITY PEDIATRICIAN'S PRESCRIPTIONS
|
Triki, N
|
|
2005
|
8 |
3 |
p. 298-299
2 p.
|
artikel
|
| 330 |
PIH5 USE OF ANTIBIOTICS IN ASSOCIATION WITH DIAGNOSES OF UPPER RESPIRATORY INFECTIONS IN A LARGE ISRAELI HMO
|
Silverman, BG
|
|
2005
|
8 |
3 |
p. 299-
1 p.
|
artikel
|
| 331 |
PIN17 A COMPARISON OF METHODS TO ASSESS QUALITY OF LIFE IN ECONOMIC ANALYSES OF HEPATITIS C TREATMENTS
|
Yeh, WS
|
|
2005
|
8 |
3 |
p. 309-310
2 p.
|
artikel
|
| 332 |
PIN11 A COST—EFFECTIVENESS ANALYSIS MODEL FOR TREATMENT OF CANDIDIASIS AND INVASIVE ASPERGILLOSIS IN MEXICO
|
Mould Ouevedo, JF
|
|
2005
|
8 |
3 |
p. 308-
1 p.
|
artikel
|
| 333 |
PIN24 ACUTE SINUSITIS OUTCOMES AND CHARGES: A COMPARISON OF TWO FLUOROQUINOLONES
|
Keating, KN
|
|
2005
|
8 |
3 |
p. 312-
1 p.
|
artikel
|
| 334 |
PIN30 ANEMIA IN HIV/AIDS PATIENTS IN THE HAART ERA CLINICAL AND HUMANISTIC IMPACT
|
Zilberberg, M
|
|
2005
|
8 |
3 |
p. 313-314
2 p.
|
artikel
|
| 335 |
PIN13 ANNUAL COST FOR THE TREATMENT OF PATIENTS HOSPITALIZED WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN THE UNITED STATES
|
Rojas, EG
|
|
2005
|
8 |
3 |
p. 308-
1 p.
|
artikel
|
| 336 |
PIN7 AN UPDATED EVALUATION OF THE COST-EFFECTIVENESS OF VACCINATING ADOLESCENTS FOR PERTUSSIS
|
Getsios, D
|
|
2005
|
8 |
3 |
p. 306-307
2 p.
|
artikel
|
| 337 |
PIN23 ARE SUBJECTS ENROLLED IN CANDIDEMIA CLINICAL TRIALS REPRESENTATIVE OF MOST HOSPITALIZED PATIENTS WITH THIS DISORDER
|
Sharma, R
|
|
2005
|
8 |
3 |
p. 311-
1 p.
|
artikel
|
| 338 |
PIN21 AWARENESS AND KNOWLEDGE OF HPV AMONG UNIVSERSITY STUDENTS ATTENDING AN HBCU
|
Bynum, SA
|
|
2005
|
8 |
3 |
p. 311-
1 p.
|
artikel
|
| 339 |
PIN25 CHRONIC RHINOSINUSITIS TREATMENT: A COMPARISON OF MOXIFLOXACIN AND LEVOFLOXACIN TREATMENT DURATION, OUTCOMES.AND CHARGES
|
Perfetto, EM
|
|
2005
|
8 |
3 |
p. 312-
1 p.
|
artikel
|
| 340 |
PIN5 COST ANALYSIS OFA FEBRILE NEUTROPENIA ALGORITHM WITH RESPECT TO EMPIRICAL ANTIFUNGAL THERAPY IN ADULT HEMATOLOGY/ONCOLOGY PATIENTS
|
Collins, CD
|
|
2005
|
8 |
3 |
p. 306-
1 p.
|
artikel
|
| 341 |
PIN29 COST OF THERAPY FORARV NAIVE HIV-INFECTED PATIENTS: FOSAMPRENAVIR / RITONAVIR VERSUS NELFINAVIR
|
Lee, WC
|
|
2005
|
8 |
3 |
p. 313-
1 p.
|
artikel
|
| 342 |
PIN3 DURATION OF ANTIBIOTIC TREATMENT IN HOSPITALIZED PATIENTS WITH COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS (CSSSI): FINDINGS FROM A CLINICAL STUDY COMPARING TIGECYCLINE AND VANCOMYCIN/AZTREONAM
|
Yu, H
|
|
2005
|
8 |
3 |
p. 305-
1 p.
|
artikel
|
| 343 |
PIN8 ECONOMIC EVALUATION OF INTRAVENOUS ITRACONAZOLE IN PRESUMED SYSTEMIC FUNGAL INFECTIONS IN NEUTROPENIC PATIENTS IN KOREA
|
Moeremans, K
|
|
2005
|
8 |
3 |
p. 307-
1 p.
|
artikel
|
| 344 |
PIN6 ECONOMIC EVALUATION OF VACCINATION AGAINST STREPTOCOCCUS PNEUMONIAE IN GERMANY INCLUDING HERD IMMUNITY EFFECTS
|
Reinert, RR
|
|
2005
|
8 |
3 |
p. 306-
1 p.
|
artikel
|
| 345 |
PIN2 EFFECT OF INAPPROPRIATE ANTIBIOTIC THERAPY ON CLINICAL OUTCOMES OF PATIENTS WITH PSEUDOMONAS AERUGINOSA BACTEREMIA
|
Rao, B
|
|
2005
|
8 |
3 |
p. 305-
1 p.
|
artikel
|
| 346 |
PIN18 ESTIMATES OF HEALTH CARE COSTS FOR LAMIVUDINE-REFRACTORY CHRONIC HEPATITIS B (CHB) PATIENTS
|
Tafesse, E
|
|
2005
|
8 |
3 |
p. 310-
1 p.
|
artikel
|
| 347 |
PIN9 EXPLORING THE COST-EFFECTIVENESS OF AN IMMUNISATION PROGRAMME FOR ROTAVIRUS GASTROENTERITIS IN THE UNITED KINGDOM
|
Lorgelly, PK
|
|
2005
|
8 |
3 |
p. 307-
1 p.
|
artikel
|
| 348 |
PIN22 HOSPITALIZED COMMUNITY ACQUIRED PNEUMONIA: A THREE YEAR REVIEW OF PATIENT FACTORS ASSOCIATED WITH PROLONGED LENGTH OF STAY
|
DePestel, DD
|
|
2005
|
8 |
3 |
p. 311-
1 p.
|
artikel
|
| 349 |
PINI6 COST-UTILITY OF CHRONIC HEPATITIS “C” TREATMENT WITH THYMOSIN ALPHA I IN MEXICO
|
Nevarez-Sida, A
|
|
2005
|
8 |
3 |
p. 309-
1 p.
|
artikel
|
| 350 |
PINI0 ECONOMIC ANALYSIS OF VACCINATION WITH MENACTRA IN THE US
|
Getsios, D
|
|
2005
|
8 |
3 |
p. 307-
1 p.
|
artikel
|
| 351 |
PIN15 IMPACT OF COMPLICATED SKIN AND SOFT TISSUE INFECTIONS ON INPATIENT COSTS FOR AN ACADEMIC MEDICAL CENTER
|
Patel, N
|
|
2005
|
8 |
3 |
p. 309-
1 p.
|
artikel
|
| 352 |
PIN4 IMPACT OF EMPIRIC ANTIFUNGAL THERAPY ON MORTALITY IN HOSPITALIZED PATIENTS WITH BLOODSTREAM CANDIDEMIA
|
Rege, M
|
|
2005
|
8 |
3 |
p. 305-306
2 p.
|
artikel
|
| 353 |
PIN20 IMPROVEMENT IN ANTIMALARIAL DRUGS ACCESS: RESULTS OF A PROGRAM PERFORMED IN YAOUNDE
|
N'Do, J
|
|
2005
|
8 |
3 |
p. 310-311
2 p.
|
artikel
|
| 354 |
PIN12 INFANTILE GASTROENTERITIS IN THE COMMUNITY: A COST OF ILLNESS STUDY
|
Lorgelly, PK
|
|
2005
|
8 |
3 |
p. 308-
1 p.
|
artikel
|
| 355 |
PINI OUTPATIENT COMMUNITY-ACQUIRED PNEUMONIA IN NON-ELDERLY ADULTS: TREATMENT AND OUTCOMES
|
Singer, ME
|
|
2005
|
8 |
3 |
p. 304-305
2 p.
|
artikel
|
| 356 |
PIN14 OUTPATIENT COMMUNITY-ACQUIRED PNEUMONIA IN NON-ELDERLY ADULTS: UTILIZATION AND COST
|
Rose, J
|
|
2005
|
8 |
3 |
p. 308-309
2 p.
|
artikel
|
| 357 |
PIN27 PROSPECTIVE OBSERVATIONAL STUDY OF PATIENT REPORTED OUTCOMES FORAZITHROMYCIN VS. USUAL CARE IN THE TREATMENT OF ACUTE BACTERIAL EXACERBATIONS OF CHRONIC BRONCHITIS
|
Milstone, AP
|
|
2005
|
8 |
3 |
p. 313-
1 p.
|
artikel
|
| 358 |
PIN28 THE COST-EFFECTIVENESS OF PREVENTING MOTHER-TO-CHILD TRANSMISSION OF HIV IN CHINA
|
Zhang, H
|
|
2005
|
8 |
3 |
p. 313-
1 p.
|
artikel
|
| 359 |
PIN31 USE OF THE SYMPTOMS DISTRESS MODULE IN AN INTERNATIONAL STUDY
|
Mear, I
|
|
2005
|
8 |
3 |
p. 314-
1 p.
|
artikel
|
| 360 |
PIN19 UTILISATION OF ANTIBIOTICS WITHIN THE SLOVAK REPUBLIC
|
Tesar, T
|
|
2005
|
8 |
3 |
p. 310-
1 p.
|
artikel
|
| 361 |
PIN26 VALIDATION OF A HEALTH-RELATED QUALITY OF LIFE INSTRUMENT FOR HEPATITIS B PATIENTS IN SINGAPORE
|
Ong, SC
|
|
2005
|
8 |
3 |
p. 312-
1 p.
|
artikel
|
| 362 |
PMC6 ACCURATE AND RAPID PREDICTION OF DRUG PLAN EXPENDITURE WHILE PLANNING REIMBURSEMENT CHANGES USING POLICY SIMULATION
|
Dormuth, CR
|
|
2005
|
8 |
3 |
p. 376-
1 p.
|
artikel
|
| 363 |
PMC10 AN INTERNET-BASED EDUCATIONAL INTERVENTION TO INCREASE KNOWLEDGE: A RAPID, EFFICIENT, AND EFFECTIVE METHOD
|
Dubois, RW
|
|
2005
|
8 |
3 |
p. 377-378
2 p.
|
artikel
|
| 364 |
PMC2 A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS OF GENETIC TESTING TECHNOLOGIES
|
Ramsey, S
|
|
2005
|
8 |
3 |
p. 375-
1 p.
|
artikel
|
| 365 |
PMC31 AT WHAT COST? A REVIEW OF DRUG ACQUISITION COST ISSUES IN MODELLED ECONOMIC EVALUATIONS.
|
Wonder, M
|
|
2005
|
8 |
3 |
p. 384-
1 p.
|
artikel
|
| 366 |
PMC33 BRIDGING BEYOND REGRESSION-ARTIFICIAL NEURAL NETWORK IN MAPPING FROM SF-36 TO HEALTH UTILITY
|
Yu, AP
|
|
2005
|
8 |
3 |
p. 384-
1 p.
|
artikel
|
| 367 |
PMC7 BRIDGING THE REQUIREMENT-CAPABILITY GAP BETWEEN DRUG PLAN DECISION MAKERS AND THEIR DATA ANALYSTS IN DRUG POLICY PLANNING
|
Burnett, S
|
|
2005
|
8 |
3 |
p. 376-377
2 p.
|
artikel
|
| 368 |
PMC21 DEVELOPING METHODOLOGY FOR THE TRANSLATION AND LINGUISTIC VALIDATION OF PATIENT REPORTED DIARIES
|
Verjee-Lorenz, A
|
|
2005
|
8 |
3 |
p. 381-
1 p.
|
artikel
|
| 369 |
PMC22 DEVELOPING SYMPTOM-BASED QUESTIONNAIRES FOR DIAGNOSTIC SCREENING
|
Nordyke, RJ
|
|
2005
|
8 |
3 |
p. 381-
1 p.
|
artikel
|
| 370 |
PMC14 EQUIVALENCE OF PAPER AND TOUCH SCREEN VERSIONS OF THE EQ-5D VISUAL ANALOG SCALE (EQ-VAS)
|
Ramachandran, S
|
|
2005
|
8 |
3 |
p. 379-
1 p.
|
artikel
|
| 371 |
PMC18 HEALTH UTILITIES INDEX (HUI) ON-LINE QUESTIONNAIRE SYSTEM: CRITERION VALIDITY OF MULTI- AND SINGLE-ATTRIBUTE UTILITY SCORES
|
Hunter, D
|
|
2005
|
8 |
3 |
p. 380-
1 p.
|
artikel
|
| 372 |
PMC19 IMPROVING THE SCALING PROPERTIES OF THE PSYCHOLOGICAL GENERAL WELL-BEING SCALE (PGWB)
|
McKenna, SP
|
|
2005
|
8 |
3 |
p. 380-
1 p.
|
artikel
|
| 373 |
PMC15 INFLUENCE OF VARIOUS HEALTH STATUS MEASURES ON TOTAL EXPENDITURES IN THE MEPS DATASET
|
De, Smet BD
|
|
2005
|
8 |
3 |
p. 379-
1 p.
|
artikel
|
| 374 |
PMC26 INTERPRETING THE MAGNITUDE OF SCORE DIFFERENCES OBJECTIVES: CONDITIONS AND OUTCOMES
|
Wallenstein, GV
|
|
2005
|
8 |
3 |
p. 382-
1 p.
|
artikel
|
| 375 |
PMC3 INTRODUCTION OF BIAS WHEN USING THE SMEARING RE-TRANSFORMATION METHOD IN THE PRESENCE OF POSITIVELY SKEWED ANTI-LOGGED RESIDUALS
|
Wang, MT
|
|
2005
|
8 |
3 |
p. 375-376
2 p.
|
artikel
|
| 376 |
PMC28 LINGUISTIC VALIDATION OF THE US SPANISH WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE, GENERAL HEALTH VERSION (WPAI:GH)
|
Gawlicki, MC
|
|
2005
|
8 |
3 |
p. 383-
1 p.
|
artikel
|
| 377 |
PMC28 LINGUISTIC VALIDATION OF THE US SPANISH WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE, GENERAL HEALTH VERSION (WPAI:GH)
|
Gawlicki, MC
|
|
2005
|
8 |
3 |
p. 382-
1 p.
|
artikel
|
| 378 |
PMC16 LINKING DISEASE-SPECIFIC QUALITY OF LIFE (QOL) SCALES
|
McKenna, SP
|
|
2005
|
8 |
3 |
p. 379-
1 p.
|
artikel
|
| 379 |
PMC27 PATIENTS' PERSPECTIVES OF TREATMENT SATISFACTION: A QUALITATIVE RESEARCH EVALUATION
|
Colman, S
|
|
2005
|
8 |
3 |
p. 382-
1 p.
|
artikel
|
| 380 |
PMC5 PERSONNEL COSTS, LEARNING CURVES, AND SCALE ECONOMIES FOR TELEPHONE-BASED NURSE INTERVENTIONS
|
Grant, W
|
|
2005
|
8 |
3 |
p. 376-
1 p.
|
artikel
|
| 381 |
PMC29 RECONSIDERING THE PERSPECTIVE IN ECONOMIC EVALUATION
|
Seoane-Vazquez, EC
|
|
2005
|
8 |
3 |
p. 383-
1 p.
|
artikel
|
| 382 |
PMC29 RECONSIDERING THE PERSPECTIVE IN ECONOMIC EVALUATION
|
Seoane-Vazquez, EC
|
|
2005
|
8 |
3 |
p. 382-383
2 p.
|
artikel
|
| 383 |
PMC20 RELATIONSHIP BETWEEN PATIENT SATISFACTION AND PERCEIVED HEALTH STATUS
|
Xiao, H
|
|
2005
|
8 |
3 |
p. 380-381
2 p.
|
artikel
|
| 384 |
PMC17 THE UK EQ-5DINDEX: AN EVALUATION OF FACE VALIDITY IN HOSPITAL TREATED SUBJECTS
|
Currie, CJ
|
|
2005
|
8 |
3 |
p. 379-380
2 p.
|
artikel
|
| 385 |
PMC4 THE USE OF A LIFE ANNUITY TO MORE ACCURATELY CALCULATE MEDICAL COSTS IN A COST-EFFECTIVENESS ANALYSIS
|
Van, Den Bos
|
|
2005
|
8 |
3 |
p. 376-
1 p.
|
artikel
|
| 386 |
PMC23 TRANSLATABILITY ASSESSEMENT: A NEW APPROACH TO INTERNATIONAL QUESTIONNAIRE DEVELOPMENT
|
Conway, K
|
|
2005
|
8 |
3 |
p. 381-
1 p.
|
artikel
|
| 387 |
PMC1 USE OF THRESHOLDS FOR SAFETY REPORTING IN CLINICAL TRIALS
|
Frame, D
|
|
2005
|
8 |
3 |
p. 375-
1 p.
|
artikel
|
| 388 |
PMC32 USING MARKOV MATRICES TO INTEGRATE RISK/BENEFIT CONSIDERATIONS OF HEALTH CARE INTERVENTIONS EVALUATED USING HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS
|
Casado, A
|
|
2005
|
8 |
3 |
p. 384-
1 p.
|
artikel
|
| 389 |
PMC13 VALUE OF ADDING MEDICAL CLAIMS DATA TO THE PHARMACY-BASED MODELS PREDICTING FUTURE HEALTH CARE COSTS AND JUMPS IN COSTS
|
Parsons, O
|
|
2005
|
8 |
3 |
p. 378-
1 p.
|
artikel
|
| 390 |
PMC11 WHICH ONE IS LOGICAL? LOGIT OR RARE EVENT LOGIT (RE-LOGIT)
|
Baser, O
|
|
2005
|
8 |
3 |
p. 378-
1 p.
|
artikel
|
| 391 |
PMH14 A CASE-CONTROL STUDY ON SECOND-GENERATION ANTIDEPRESSANT USE IN PATIENTS WITH BIPOLAR DISORDER
|
Fu, AZ
|
|
2005
|
8 |
3 |
p. 388-389
2 p.
|
artikel
|
| 392 |
PMH28 A COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM AND SERTRALINE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
|
Armstrong, EP
|
|
2005
|
8 |
3 |
p. 393-
1 p.
|
artikel
|
| 393 |
PMH18 AN EXPLORATORY STUDY TO DEVELOP A MODEL OF QUALITY OF LIFE FOR BIPOLAR DISORDER
|
Doward, LC
|
|
2005
|
8 |
3 |
p. 390-
1 p.
|
artikel
|
| 394 |
PMH11 ANTIPSYCHOTIC USE AND HOSPITALIZATION IN BIPOLAR OR MANIC PATIENTS
|
Gianfrancesco, F
|
|
2005
|
8 |
3 |
p. 387-388
2 p.
|
artikel
|
| 395 |
PMH32 APPROPRIATENESS AND VARIATION IN DRUG UTILIZATION ACROSS PATIENTS WITH DEPRESSION
|
Long, S
|
|
2005
|
8 |
3 |
p. 394-
1 p.
|
artikel
|
| 396 |
PMH50 A PSYCHIATRIC HOSPITAL REVENUE AND PROFITABILITY MODEL FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA IN JAPAN
|
Makino, K
|
|
2005
|
8 |
3 |
p. 400-
1 p.
|
artikel
|
| 397 |
PMH8 A REVIEW OF THE ECONOMIC BURDEN OF ADHD
|
Matza, LS
|
|
2005
|
8 |
3 |
p. 386-387
2 p.
|
artikel
|
| 398 |
PMH23 ASSESSING VENLAFAXINE, SERTRALINE, OR PLACEBO TREATMENT ON IMPROVEMENT IN GENERAL LIFE FUNCTIONING AMONG DEPRESSED PATIENTS
|
Zhang, HF
|
|
2005
|
8 |
3 |
p. 391-
1 p.
|
artikel
|
| 399 |
PMH37 A SYSTEMATIC REVIEW OF SUICIDALITY MEASURES IN STUDIES USING SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN CHILDREN AND ADOLESCENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
|
Pfalzgraf, AR
|
|
2005
|
8 |
3 |
p. 395-396
2 p.
|
artikel
|
| 400 |
PMH55 CLASSIFYING ANTIPSYCHOTIC ADHERENCE USING LATENT CLASSES ANALYSIS: CHARACTERISTICS OF NON-ADHERENT CASEMIX IN THE CALIFORNIA MEDICAID (MEDICAL) PROGRAM
|
Ahn, J
|
|
2005
|
8 |
3 |
p. 401-402
2 p.
|
artikel
|
| 401 |
PMH38 COMPARING EXHAUSTIVE CHAID CLASSIFICATION TREE AND FORWARD STEPWISE LOGISTIC REGRESSION (LR) IN EXPLAINING THE PRESCRIBING OF ANTIDEPRESSANTS
|
Tan, H
|
|
2005
|
8 |
3 |
p. 396-
1 p.
|
artikel
|
| 402 |
PMH17 COMPARING PROPENSITY SCORE AND DIFFERENCE-IN-DIFFERENCE METHODS: SECOND-GENERATION ANTIDEPRESSANT USE FOR BIPOLAR DISORDER
|
Fu, AZ
|
|
2005
|
8 |
3 |
p. 389-390
2 p.
|
artikel
|
| 403 |
PMH61 COMPARISON OF OUTCOMES REPORTED BY INDIVIDUALS WITH SCHIZOPHRENIA RESIDING IN THE COMMUNITY AND OBJECTIVE OUTCOMES REPORTED BY CAREGIVERS
|
Barr, J
|
|
2005
|
8 |
3 |
p. 403-404
2 p.
|
artikel
|
| 404 |
PMH25 COST AND UTILIZATION DIFFERENCES AMONG CARDIAC PATIENTS TREATED FOR DEPRESSION WITH ZOLOFT VERSUS NO PHARMACEUTICAL TREATMENT
|
Bron, MS
|
|
2005
|
8 |
3 |
p. 392-
1 p.
|
artikel
|
| 405 |
PMH26 COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN TURKEY
|
Hemels, ME
|
|
2005
|
8 |
3 |
p. 392-
1 p.
|
artikel
|
| 406 |
PMH51 COST-EFFECTIVENESS EVALUATION OF LONG-ACTING RISPERIDONE
|
Locklear, J
|
|
2005
|
8 |
3 |
p. 400-
1 p.
|
artikel
|
| 407 |
PMH4 COST-EFFECTIVENESS OF ALPRAZOLAM IN ANXIETY DISORDERS
|
García-Contreras, F
|
|
2005
|
8 |
3 |
p. 385-386
2 p.
|
artikel
|
| 408 |
PMH27 COST-EFFECTIVENESS OF ESCITALOPRAM VS. VENLAFAXIN XR IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN GERMANY
|
Kulp, W
|
|
2005
|
8 |
3 |
p. 392-393
2 p.
|
artikel
|
| 409 |
PMH21 COSTS OF DEMENTIA AMONG COMMUNITY DWELLING PATIENTS
|
Maneno, M
|
|
2005
|
8 |
3 |
p. 391-
1 p.
|
artikel
|
| 410 |
PMH2 COSTS OF TREATING CRISIS-PRONE SCHIZOPHRENIA PATIENTS
|
Zhu, B
|
|
2005
|
8 |
3 |
p. 256-257
2 p.
|
artikel
|
| 411 |
PMH6 DETERMINANTS OF PERMANENT NUSRING HOME ADMISSIONS AMONG ELDERLY IN THE UNITED STATES
|
Cai, QC
|
|
2005
|
8 |
3 |
p. 386-
1 p.
|
artikel
|
| 412 |
PMH54 DIFFERENTIAL RISKS AND ASSOCIATED COSTS OF HOSPITALIZATION DURING ANTIPSYCHOTIC TREATMENT IN MEDICAID PATIENTS WITH SCHIZOPHRENIA
|
Gianfrancesco, F
|
|
2005
|
8 |
3 |
p. 401-
1 p.
|
artikel
|
| 413 |
PMH53 DIRECT HEALTH CARE COSTS OF SCHIZOPHRENIA IN THE UNITED STATES: 2002
|
Ascher-Svanum, H
|
|
2005
|
8 |
3 |
p. 401-
1 p.
|
artikel
|
| 414 |
PMH33 DRUG UTILIZATION AND MARKET-SHARE COMPETITION AMONG ANTIDEPRESSANT MEDICATIONS IN US MEDICAID PROGRAMS
|
Guo, JJ
|
|
2005
|
8 |
3 |
p. 394-395
2 p.
|
artikel
|
| 415 |
PMH5 ECONOMIC BURDEN OF GENERALIZED ANXIETY DISORDER (GAD) AND OTHER ANXIETY DISORDERS
|
Chang, S
|
|
2005
|
8 |
3 |
p. 386-
1 p.
|
artikel
|
| 416 |
PMH57 ELECTRONIC MONITORING OF ANTIPSYCHOTIC ADHERENCE OF OUTPATIENTS WITH SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER AND ASSOCIATION WITH SYMPTOMS, QUALITY OF LIFE AND COGNITION
|
Byerly, M
|
|
2005
|
8 |
3 |
p. 402-
1 p.
|
artikel
|
| 417 |
PMH49 ESTIMATING ANNUAL US PREVALENCE OF SCHIZOPHRENIA IN 2002
|
Wu, EQ
|
|
2005
|
8 |
3 |
p. 399-400
2 p.
|
artikel
|
| 418 |
PMH9 ESTIMATING THE BUDGET IMPACT OF QUETIAPINE FOR THE TREATMENT OF ACUTE MANIA AMONG HOSPITALIZED PATIENTS
|
Caro, JJ
|
|
2005
|
8 |
3 |
p. 387-
1 p.
|
artikel
|
| 419 |
PMH63 GREATER DEPRESSIVE SYMPTOMS ARE ASSOCIATED WITH WORSE FUNCTIONAL OUTCOMES IN PATIENTS DIAGNOSED WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER
|
Phillips, GA
|
|
2005
|
8 |
3 |
p. 404-
1 p.
|
artikel
|
| 420 |
PMH1 HEALTH CARE AND WORKLOSS COSTS OF OPIOID ABUSE AMONG AN EMPLOYED POPULATION IN THE US
|
White, AG
|
|
2005
|
8 |
3 |
p. 384-385
2 p.
|
artikel
|
| 421 |
PMH45 HISTORY OF SUBSTANCE ABUSE ASSOCIATED WITH POOR PROGNOSIS IN THE TREATMENT OF SCHIZOPHRENIA: RESULTS FROM A CLINICAL TRIAL DATABASE
|
Kinon, B
|
|
2005
|
8 |
3 |
p. 398-
1 p.
|
artikel
|
| 422 |
PMH42 HOSPITALIZATION AND EMERGENCY ROOM VISITS BEFORE AND AFTER TREATMENT WITH ATYPICAL ANTIPSYCHOTICS
|
Rajagopalan, K
|
|
2005
|
8 |
3 |
p. 397-
1 p.
|
artikel
|
| 423 |
PMH43 IMPACT OF A PSYCHOEDUCATION PROGRAM ON HEALTH STATUS OF SEVERE AND PERSISTENTLY MENTALLY ILL
|
Bellnier, T
|
|
2005
|
8 |
3 |
p. 397-398
2 p.
|
artikel
|
| 424 |
PMH65 IMPACT OF ATYPICAL AGENTS ON OUTCOMES OF CARE IN SCHIZOPHRENIC PATIENTS
|
Joyce, AT
|
|
2005
|
8 |
3 |
p. 405-
1 p.
|
artikel
|
| 425 |
PMH34 IMPACT OF RELABELING ON NEFAZODONE PRESCRIBING: A RISK MINIMIZATION EVALUATION
|
Morrato, EH
|
|
2005
|
8 |
3 |
p. 395-
1 p.
|
artikel
|
| 426 |
PMH24 IMPROVEMENT OF FATIGUE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH VENLAFAXINE, SERTRALINE, OR PLACEBO
|
Zhang, HF
|
|
2005
|
8 |
3 |
p. 392-
1 p.
|
artikel
|
| 427 |
PMH16 MEASURING THE EFFECT OF A POLICY CHANGE IN MONTHLY PRESCRIPTION LIMIT ON HEALTH CARE UTILIZATION AND EXPENDITURE: A CONTROLLED COMPARISON OF OLS AND PANEL ESTIMATION
|
Hassan, MK
|
|
2005
|
8 |
3 |
p. 389-
1 p.
|
artikel
|
| 428 |
PMH10 MENTAL HEALTH COST COMPARISON AMONG PATIENTS WITH BIPOLAR DISORDER TREATED WITH RISPERIDONE VERSUS OLANZAPINE OR QUETIAPINE IN A MANAGED CARE SETTING: A PROPENSITY-MATCHED COHORT STUDY
|
Caro, JJ
|
|
2005
|
8 |
3 |
p. 387-
1 p.
|
artikel
|
| 429 |
PMH30 OUTCOME ANALYSIS OF A MULTI-LEVEL INTERVENTION PROGRAM TO IMPROVE ANTIDEPRESSANT MEDICATION ADHERENCE
|
Alison, L
|
|
2005
|
8 |
3 |
p. 393-394
2 p.
|
artikel
|
| 430 |
PMH20 PATTERNS OF DEMENTIA/ALZHEIMER MANAGEMENT AMONG ELDERLY PATIENTS IN US AMBULATORY CARE
|
Maneno, M
|
|
2005
|
8 |
3 |
p. 390-391
2 p.
|
artikel
|
| 431 |
PMH44 PERCEPTION OF SIDE EFFECTS MEDICATION ADHERENCE AND QUALITY OF LIFE IN PSYCHIATRIC PATIENTS
|
Lapshin, O
|
|
2005
|
8 |
3 |
p. 398-
1 p.
|
artikel
|
| 432 |
PMH22 PREDICTORS OF HEALTH RELATED QUALITY OF LIFE AMONG DEMENTIA CAREGIVERS: A LONGITUDINAL EXAMINATION
|
Madan, A
|
|
2005
|
8 |
3 |
p. 391-
1 p.
|
artikel
|
| 433 |
PMH12 PREVALANCE AND COST OF BIPOLAR DISORDER AND TREATMENT WITHIN A MANAGED CARE ORGANIZATION
|
Lew, KH
|
|
2005
|
8 |
3 |
p. 388-
1 p.
|
artikel
|
| 434 |
PMH3 QUALITY-ADJUSTED LIFE YEARS GAINED WITH BUPRENORPHINE TREATMENT FOR OPIATE ADDICTION
|
Campbell, HM
|
|
2005
|
8 |
3 |
p. 385-
1 p.
|
artikel
|
| 435 |
PMH40 QUALITY-ADJUSTED REMISSION FREE DAYS: AN EXTENDED Q-TWIST APPLICATION IN MAJOR DEPRESSION DISORDER
|
Zhang, HF
|
|
2005
|
8 |
3 |
p. 396-397
2 p.
|
artikel
|
| 436 |
PMH41 QUALITY OF LIFE, EMOTIONAL AND PHYSICAL SYMPTOMS IN DEPRESSION: A LITERATURE REVIEW OF SYMPTOMATOLOGY AND PATIENT REPORTED OUTCOME (PRO) INSTRUMENTS
|
Garcia-Cebrian, A
|
|
2005
|
8 |
3 |
p. 397-
1 p.
|
artikel
|
| 437 |
PMH36 RASCH MODEL COMPARISON OF BECK DEPRESSION INDEX AND MOOD AND ANXIETY SYMPTOMS QUESTIONNAIRE IN MEASUREMENT OF DEPRESSION
|
Wang, ZX
|
|
2005
|
8 |
3 |
p. 395-
1 p.
|
artikel
|
| 438 |
PMH46 RELIABILITY AND VALIDITY OF THE READINESS FOR DISCHARGE QUESTIONNAIRE IN SCHIZOPHRENIA
|
Ruetsch, C
|
|
2005
|
8 |
3 |
p. 398-399
2 p.
|
artikel
|
| 439 |
PMH56 STARTING DOSE AND PERSISTENCE FOR ZIPRASIDONE USERS IN MEDICAID
|
Mullins, CD
|
|
2005
|
8 |
3 |
p. 402-
1 p.
|
artikel
|
| 440 |
PMH15 STUDY GAPS IN ECONOMIC EVALUATIONS OF PHARMACOTHERAPY IN BIPOLAR DISORDER
|
Hassan, MK
|
|
2005
|
8 |
3 |
p. 389-
1 p.
|
artikel
|
| 441 |
PMH48 SYSTEMATIC REVIEW ON RELAPSE AND ANTIPSYCHOTIC NON-ADHERENCE IN SCHIZOPHRENIA
|
Shi, L
|
|
2005
|
8 |
3 |
p. 399-
1 p.
|
artikel
|
| 442 |
PMH13 THE CLINICAL AND ECONOMIC OUTCOMES OF SECOND-GENERATION ANTIDEPRESSANT USE FOR BIPOLAR DISORDER
|
Fu, AZ
|
|
2005
|
8 |
3 |
p. 388-
1 p.
|
artikel
|
| 443 |
PMH52 THE COST OF RELAPSE IN SCHIZOPHRENIA IN THE UNITED STATES
|
Ascher-Svanum, H
|
|
2005
|
8 |
3 |
p. 400-401
2 p.
|
artikel
|
| 444 |
PMH29 THE EFFECT OF RAISING THREE TIER COPAYMENTS ON SSRI COMPLIANCE RATES
|
Bron, MS
|
|
2005
|
8 |
3 |
p. 393-
1 p.
|
artikel
|
| 445 |
PMH7 THE EFFECT OF VENLAFAXINE, PAROXETINE, AND PLACEBO ON HEALTH-RELATED WORK PRODUCTIVITY IN PANIC DISORDER PATIENTS
|
Khandker, R
|
|
2005
|
8 |
3 |
p. 386-
1 p.
|
artikel
|
| 446 |
PMH58 THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY—E-STAR: BASELINE RESULTS FOR GERMANY
|
Naber, D
|
|
2005
|
8 |
3 |
p. 402-403
2 p.
|
artikel
|
| 447 |
PMH59 THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY—E-STAR: BASELINE RESULTS FOR GERMANY, SPAIN AND AUSTRALIA
|
Rossillon, D
|
|
2005
|
8 |
3 |
p. 403-
1 p.
|
artikel
|
| 448 |
PMH60 THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY—E-STAR: DATA QUALITY ASSURANCE GATE KEEPING METHODS
|
Farmer, D
|
|
2005
|
8 |
3 |
p. 403-
1 p.
|
artikel
|
| 449 |
PMH35 THE MAIN AND INTERACTION EFFECTS OF PATIENT AND PHYSICIAN CHARACTERISTICS IN INFLUENCING THE PRESCRIBING OF ANTIDEPRESSANTS
|
Tan, H
|
|
2005
|
8 |
3 |
p. 395-
1 p.
|
artikel
|
| 450 |
PMH31 THE RELATIVE PERFORMANCE OF NEWER ANTIDEPRESSANTS IN A MEDICAID POPULATION
|
McCombs, JS
|
|
2005
|
8 |
3 |
p. 394-
1 p.
|
artikel
|
| 451 |
PMH39 THE USEFULNESS OF THE EQ-5D IN DIFFERENTIATING AMONG PERSONS WITH MAJOR DEPRESSIVE EPISODE AND ANXIETY
|
Supina, AL
|
|
2005
|
8 |
3 |
p. 396-
1 p.
|
artikel
|
| 452 |
PMH19 TREATMENT ADHERENCE WITH ANTIPSYCHOTICS AMONG BIPOLAR AND MANIC PATIENTS
|
Gianfrancesco, F
|
|
2005
|
8 |
3 |
p. 390-
1 p.
|
artikel
|
| 453 |
PMH47 USE AND COST OF POLYPHARMACY IN SCHIZOPHRENIA: DATA FROM A RANDOMIZED, DOUBLE-BLIND STUDY OF RISPERIDONE AND QUETIAPINE
|
Rupnow, MF
|
|
2005
|
8 |
3 |
p. 399-
1 p.
|
artikel
|
| 454 |
PMH64 USE OF THE CAREGIVER STRAIN QUESTIONNAIRE IN AN INTERNATIONAL STUDY
|
Phillips, GA
|
|
2005
|
8 |
3 |
p. 404-
1 p.
|
artikel
|
| 455 |
PMH62 VALUATION OF SCHIZOPHRENIA-RELATED HEALTH STATES BY THE GENERAL POPULATION USING THE AQOL, TIME TRADE-OFF AND VISUAL ANALOGUE SCALES
|
Adams, J
|
|
2005
|
8 |
3 |
p. 404-
1 p.
|
artikel
|
| 456 |
PMS2 EVALUATION OF AN AUTOMATED SYSTEM FOR PRIOR AUTHORIZATION—A COX-2 INHIBITOR EXAMPLE
|
Carroll, NV
|
|
2005
|
8 |
3 |
p. 405-
1 p.
|
artikel
|
| 457 |
PMS1 INCREMENTAL DIRECT COST OF BACK PAIN IN THE UNITED STATES IN 2001
|
Balu, S
|
|
2005
|
8 |
3 |
p. 405-
1 p.
|
artikel
|
| 458 |
PNL11 AN ECONOMIC EVALUATION OFTRIPTAN PRODUCTS FOR MIGRAINE
|
Perfetto, EM
|
|
2005
|
8 |
3 |
p. 317-
1 p.
|
artikel
|
| 459 |
PNL9 CARE COSTS OF PARTIAL REFRACTORY EPILEPSY IN MEXICO
|
Castro-Rios, A
|
|
2005
|
8 |
3 |
p. 317-
1 p.
|
artikel
|
| 460 |
PNL31 CLINICAL PRIOR AUTHORIZATION PROGRAM: A STRATEGY FOR CONTROLLING DRUG EXPENDITURES AMONG PATIENTS WITH INSOMNIA
|
Sun, SX
|
|
2005
|
8 |
3 |
p. 324-
1 p.
|
artikel
|
| 461 |
PNL25 COST AND USE OF PARKINSONISM-INDUCING DRUGS AMONG MEDICARE BENEFICIARIES
|
Noyés, K
|
|
2005
|
8 |
3 |
p. 322-
1 p.
|
artikel
|
| 462 |
PNL13 COST-EFFECTIVENESS OF ELETRIPTAN VERSUS ZOLMITRIPTAN: RESULTS FROM A RANDOMIZED CONTROLLED TRIAL
|
Mullins, CD
|
|
2005
|
8 |
3 |
p. 318-
1 p.
|
artikel
|
| 463 |
PNL29 COST-EFFECTIVENESS OF LONGER-TERM TREATMENT WITH ESZOPICLONE 3MG IN ADULTS WITH PRIMARY INSOMNIA
|
Botteman, M
|
|
2005
|
8 |
3 |
p. 323-
1 p.
|
artikel
|
| 464 |
PNL22 COST-EFFECTIVENESS OF PRAMIPEXOLE COMPARED WITH PIRIBEDIL IN EARLY PARKINSON'S DISEASE PATIENTS
|
Chikina, ES
|
|
2005
|
8 |
3 |
p. 321-
1 p.
|
artikel
|
| 465 |
PNL23 COST-UTILITY ANALYSIS FOR EARLY PATIENTS WITH PARKINSON'S DISEASE TREATED BY DOPAMINE AGONISTS
|
Chikina, ES
|
|
2005
|
8 |
3 |
p. 321-
1 p.
|
artikel
|
| 466 |
PNL16 DEVELOPMENT OF A UNIQUE INTERNET & PHONE BASED SYSTEM TO CAPTURE MIGRAINE TREATMENT OUTCOMES
|
Ambegaonkar, AJ
|
|
2005
|
8 |
3 |
p. 319-
1 p.
|
artikel
|
| 467 |
PNL19 DEVELOPMENT OF THE MULTIPLE SCLEROSIS TREATMENT SATISFACTION QUESTIONNAIRE (MSTCQ)
|
Cramer, JA
|
|
2005
|
8 |
3 |
p. 320-
1 p.
|
artikel
|
| 468 |
PNL7 DIAGNOSING PHYSICIANS, PRESCRIPTION CHOICE AND PATTERNS FOR ALZHEIMER'S DISEASE IN CALIFORNIA MEDICAID PROGRAM
|
Yu, AP
|
|
2005
|
8 |
3 |
p. 316-
1 p.
|
artikel
|
| 469 |
PNL5 DRUG PERSISTENCY OF TWO CHOLINESTERASE INHIBITORS—RIVASTIGMINE VERSUS DONEPEZIL AMONG ELDERLY PATIENTS WITH ALZHEIMER'S DISEASE
|
Suh, DC
|
|
2005
|
8 |
3 |
p. 315-316
2 p.
|
artikel
|
| 470 |
PNL17 EFFECT OF IMMUNOMODULATORYTHERAPYAND OTHER FACTORS ON PRODUCTIVITY IN MS
|
Lage, MJ
|
|
2005
|
8 |
3 |
p. 319-
1 p.
|
artikel
|
| 471 |
PNL30 FORECASTING THE IMPACT OF ADDING A NEW DRUG ON FORMULARY USING MEDICAL CLAIMS DATA AND CLINICAL LITERATURE: A CASE STUDY OF INSOMNIA TREATMENT
|
Ozminkowski, R
|
|
2005
|
8 |
3 |
p. 323-
1 p.
|
artikel
|
| 472 |
PNL21 FUNCTIONAL LIMITATIONS, MENTAL HEALTH, AND RESOURCE USE ASSOCIATED WITH THE HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH RESTLESS LEGS SYNDROME
|
Martin, MC
|
|
2005
|
8 |
3 |
p. 320-321
2 p.
|
artikel
|
| 473 |
PNL15 FURTHER VALIDATION OF THE MIGRAINE TREATMENT SATISFACTION MEASURE
|
Martin, ML
|
|
2005
|
8 |
3 |
p. 318-319
2 p.
|
artikel
|
| 474 |
PNLI ASSESSMENT OF COMORBIDITY AND INCIDENCE RATE OF ALZHEIMER'S DISEASE IN THE CALIFORNIA MEDICAID (MEDI-CAL) PROGRAM
|
Yu, YF
|
|
2005
|
8 |
3 |
p. 314-
1 p.
|
artikel
|
| 475 |
PNL14 IMPACT OF MIGRAINE FREQUENCY ON HEALTH UTILITIES
|
Brown, J
|
|
2005
|
8 |
3 |
p. 318-
1 p.
|
artikel
|
| 476 |
PNL4 NURSING HOME RESIDENTS WITH ALZHEIMER'S DISEASE: CHANGES IN MANAGEMENT LEVELSAND COSTS OVER A SIX YEAR PERIOD
|
O'Brien, J
|
|
2005
|
8 |
3 |
p. 315-
1 p.
|
artikel
|
| 477 |
PNL6 OUTCOMES OFANTIDEPRESSANT USE IN PATIENTS WITH ALZHEIMER'S DISEASE IN THE CALIFORNIA MEDICAID PROGRAM
|
Yu, YF
|
|
2005
|
8 |
3 |
p. 316-
1 p.
|
artikel
|
| 478 |
PNL24 PATTERNS OF RESOURCE USE IN PATIENTS WITH DIFFERENT SEVERITIES OF PARKINSON'S DISEASE
|
Emmermann, A
|
|
2005
|
8 |
3 |
p. 321-322
2 p.
|
artikel
|
| 479 |
PNL32 PHYSICIAN AND PATIENT DETERMINANTS OF THE TREATMENT OF SLEEP DIFFICULTIES IN OUTPATIENT SETTINGS IN THE UNITED STATES
|
Rasu, R
|
|
2005
|
8 |
3 |
p. 324-
1 p.
|
artikel
|
| 480 |
PNL27 PREVALENCE OF INSOMNIA AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN A LARGE DATABASE
|
Vallarino, C
|
|
2005
|
8 |
3 |
p. 322-
1 p.
|
artikel
|
| 481 |
PNL10 PSYCHOMETRIC EVALUATION OF EPILEPSY-SPECIFIC QUALITY OF LIFE INSTRUMENTS
|
Oyelowo, O
|
|
2005
|
8 |
3 |
p. 317-
1 p.
|
artikel
|
| 482 |
PNL20 RESTLESS LEGS SYNDROME PLACES A SUBSTANTIAL BURDEN ON THE HEALTH-RELATED QUALITY OF LIFE OF US AND EUROPEAN PATIENTS
|
Martin, MC
|
|
2005
|
8 |
3 |
p. 320-
1 p.
|
artikel
|
| 483 |
PNL34 SEDATIVE HYPNOTICS EMPLOYED TO TREAT PATIENTS WITH AND WITHOUT INSOMNIA COMPLAINTS IN THE NATIONAL AMBULATORY MEDICAL CARE SURVEY: 1997–2002
|
Tan, LSM
|
|
2005
|
8 |
3 |
p. 324-325
2 p.
|
artikel
|
| 484 |
PNL33 SLEEP COMPLAINTS AND DIAGNOSES IN THE NATIONAL AMBULATORY MEDICAL CARE SURVEY: 1997–2002
|
Tan, LSM
|
|
2005
|
8 |
3 |
p. 324-
1 p.
|
artikel
|
| 485 |
PNL2 THE COST-EFFECTIVENESS OF DONEPEZILAND RIVASTIGMINE IN THE TREATMENT OF ALZHEIMER'S DISEASE IN THAILAND PRIVATE HOSPITAL
|
Pattanaprateep, O
|
|
2005
|
8 |
3 |
p. 314-315
2 p.
|
artikel
|
| 486 |
PNL3 THE COST-EFFECTIVENESS OF QUETIAPINE FOR ALZHEIMER'S DISEASE IN COMMUNITY DWELLING PATIENTS
|
Getsios, D
|
|
2005
|
8 |
3 |
p. 315-
1 p.
|
artikel
|
| 487 |
PNL18 THE IMPACT OF MEDICARE PART D ON ECONOMIC BARRIERS TO PRESCRIPTION MEDICATIONS AMONG BENEFICIARIES WITH MULTIPLE SCLEROSIS
|
Lundy, JJ
|
|
2005
|
8 |
3 |
p. 319-320
2 p.
|
artikel
|
| 488 |
PNL28 THE PREVALENCE OF INSOMNIA IN PATIENTS WITH DRUG DEPENDENCY OR ABUSE
|
Xu, Y
|
|
2005
|
8 |
3 |
p. 322-323
2 p.
|
artikel
|
| 489 |
PNL26 TREATMENT SATISFACTION AND PRINCIPAL CAUSES OF TERMINATION OF DRUG TREATMENT OF PARKINSON'S DISEASE IN RUSSIA
|
Chikina, ES
|
|
2005
|
8 |
3 |
p. 322-
1 p.
|
artikel
|
| 490 |
PNL12 TRIPTANS FOR MIGRAINE THERAPY: A COMPARISON BASED ON NUMBER NEEDED TO TREAT AND DOSES NEEDED TO TREAT
|
Mullins, CD
|
|
2005
|
8 |
3 |
p. 318-
1 p.
|
artikel
|
| 491 |
PNL8 USING A TOUCHTONE TELEPHONE TO COLLECT DATA FROM ELDERLY CAREGIVERS OF PATIENTS WITH ALZHEIMER'S DISEASE
|
Payne, K
|
|
2005
|
8 |
3 |
p. 316-317
2 p.
|
artikel
|
| 492 |
PNL35 USING PATIENT REPORTED OUTCOMES (PROS) TO DETERMINE THE PREVALENCE OF INSOMNIA IN FOUR COUNTRIES
|
Edmondson, M
|
|
2005
|
8 |
3 |
p. 325-
1 p.
|
artikel
|
| 493 |
POB1 COMPARISON OF WEIGHT REDUCTION AND SATISFACTION OF ORLISTAT AND SIBUTRAMINE
|
Mekaroonreung, S
|
|
2005
|
8 |
3 |
p. 405-406
2 p.
|
artikel
|
| 494 |
POB5 COST EFFECTIVENESS OF SIBUTRAMINE IN THE LONG-TERM OUTCOMES OF SIBUTRAMINE EFFECTIVENESS ON WEIGHT STUDY
|
Malone, D
|
|
2005
|
8 |
3 |
p. 407-
1 p.
|
artikel
|
| 495 |
POB6 COSTS OF OBESITY IN THE UNITED STATES AND EUROPE: A REVIEW OF THE LITERATURE
|
Budhiarso, I
|
|
2005
|
8 |
3 |
p. 407-
1 p.
|
artikel
|
| 496 |
POB7 LIFETIME COSTS ASSOCIATED WITH OBESITY: A COMPUTER SIMULATION MODEL
|
Tucker, DM
|
|
2005
|
8 |
3 |
p. 407-
1 p.
|
artikel
|
| 497 |
POB3 PREVALENCE TRENDS OF OVERWEIGHT AND OBESITY AND TREATMENT PATTERNS FOR WEIGHT CONTROL IN THE US POPULATION
|
Valiyeva, L
|
|
2005
|
8 |
3 |
p. 406-
1 p.
|
artikel
|
| 498 |
POB2 RECENT TRENDS AND A FUTURE FORECAST OF POPULATION BODY MASS INDEX LEVELS IN THE UNITED KINGDOM
|
Woehl, A
|
|
2005
|
8 |
3 |
p. 406-
1 p.
|
artikel
|
| 499 |
POB4 RELIABLE MEASUREMENT OF OBESITY: RISK OF VASCULAR DISEASE COMPLICATIONS AS A FUNCTION OF BODY MASS INDEX AND WAIST-TO- HIP RATIO
|
Woehl, A
|
|
2005
|
8 |
3 |
p. 406-407
2 p.
|
artikel
|
| 500 |
POS2 ALENDRONATE AND HORMONE REPLACEMENT THERAPY (HRT) IN THE PREVENTION OF OSTEOPOROTIC FRACTURE IN THE DEPARTMENT OF DEFENSE (DOD): AN ANALYSIS USING NET-BENEFIT REGRESSION
|
Tiller, KW
|
|
2005
|
8 |
3 |
p. 408-
1 p.
|
artikel
|
| 501 |
POS3 COST-EFFECTIVENESS ANALYSIS OF BIPHOSPHONATES AND RALOXIFENE FOR TREATMENT OF OSTEOPOROSIS AND PREVENTION OF FRACTURES
|
Lau, TC
|
|
2005
|
8 |
3 |
p. 408-
1 p.
|
artikel
|
| 502 |
POS4 FACTORS AFFECTING THE BONE DENSITY TEST PRESCRIBING FOR OSTEOPOROSIS IN MALE AMBULATORY PATIENTS
|
Rahman, A
|
|
2005
|
8 |
3 |
p. 408-409
2 p.
|
artikel
|
| 503 |
POS6 IMPACT OF AN OSTEOPOROSIS INTERVENTION PROGRAM OF PATIENTS WITH A FRACTURE HISTORY
|
Park, J
|
|
2005
|
8 |
3 |
p. 409-
1 p.
|
artikel
|
| 504 |
POS5 POST-OSTEOPOROTIC FRACTURE DRUG TREATMENT FOR OSTEOPOROSIS IN NURSING HOME ELDERLY
|
Ye, X
|
|
2005
|
8 |
3 |
p. 409-
1 p.
|
artikel
|
| 505 |
POS1 USING A BUDGET IMPACT MODEL TO PREDICT FIRST-YEAR USE OF A NEW OSTEOPOROSIS THERAPY
|
Sasser, A
|
|
2005
|
8 |
3 |
p. 408-
1 p.
|
artikel
|
| 506 |
POS7 VALIDATION STUDY OF THE OSTEOPOROSIS PATIENT SATISFACTION QUESTIONNAIRE (OPSAT-Q)
|
Flood, E
|
|
2005
|
8 |
3 |
p. 409-410
2 p.
|
artikel
|
| 507 |
PPN7 CONFIRMATORY FACTOR ANALYSIS OF THE BECK DEPRESSION INVENTORY
|
Panjabi, SS
|
|
2005
|
8 |
3 |
p. 412-
1 p.
|
artikel
|
| 508 |
PPN8 DEVELOPMENT OF DIFFERENT LANGUAGE VERSIONS OF A US BACK PAIN QUESTIONNAIRE
|
Panjabi, SS
|
|
2005
|
8 |
3 |
p. 412-
1 p.
|
artikel
|
| 509 |
PPN2 EVALUATION OF THE DIRECT COSTS OF PURE NEUROPATHIC PAIN MANAGEMENT IN FRANCE BEFORE A FIRST CONSULTATION IN A PAIN MANAGEMENT CENTER
|
Duru, G
|
|
2005
|
8 |
3 |
p. 410-
1 p.
|
artikel
|
| 510 |
PPN4 PARENTS' PERCEPTION OF THE SAFETY OF PEDIATRIC NON-PRESCRIPTION DRUGS—ACETAMINOPHEN AS AN EXAMPLE
|
Rabinovich, M
|
|
2005
|
8 |
3 |
p. 411-
1 p.
|
artikel
|
| 511 |
PPN10 PATIENT SATISFACTION WITH PAIN MANAGEMENT 28 DAYS AFTER TOTAL KNEE ARTHROPLASTY
|
Strassels, SA
|
|
2005
|
8 |
3 |
p. 413-
1 p.
|
artikel
|
| 512 |
PPN1 REDUCING MORTALITY IN PATIENTS WITH SUBSTANCE ABUSE AND CHRONIC NON-MALIGNANT PAIN THROUGH A MULTIDISCIPLINARY OPIOID RENEWAL CLINIC
|
Sampson, JM
|
|
2005
|
8 |
3 |
p. 410-
1 p.
|
artikel
|
| 513 |
PPN6 RETROSPECTIVE ANALYSIS OF DRUG UTILIZATION PATTERNS IN CANCER AND NON-CANCER PATIENTS TRANSDERMAL FENTANYL
|
Poulsen, Nautrup B
|
|
2005
|
8 |
3 |
p. 411-412
2 p.
|
artikel
|
| 514 |
PPN9 SEVERE PAIN IN PERSONS WHO RECEIVED HOSPICE CARE IN THE UNITED STATES (US)
|
Strassels, SA
|
|
2005
|
8 |
3 |
p. 412-
1 p.
|
artikel
|
| 515 |
PPN3 SUMMARY OF HOSPITAL LOGISTICS ASSOCIATED WITH INTRAVENOUS PATIENT-CONTROLLED ANALGESIA (IV PCA) FOR ACUTE POSTOPERATIVE PAIN MANAGEMENT
|
Zhang, M
|
|
2005
|
8 |
3 |
p. 410-411
2 p.
|
artikel
|
| 516 |
PPN5 TYPES OF PROBLEMS ASSOCIATED WITH INTRAVENOUS PATIENT-CONTROLLED ANALGESIA (IV PCA) INFUSION PUMPS:AN ANALYSIS OF THE MANUFACTURER AND USER FACILITY DEVICE EXPERIENCE (MAUDE) DATABASE
|
Hankin, C
|
|
2005
|
8 |
3 |
p. 411-
1 p.
|
artikel
|
| 517 |
PRS3 ACUTE EXACERBATION OF CHRONIC BRONCHITIS (AECB) TREATMENT EFFECTIVENESS: COMPARISON OF MACROLIDES TO FLUOROQUINOLONES
|
Wu, EQ
|
|
2005
|
8 |
3 |
p. 326-
1 p.
|
artikel
|
| 518 |
PRS9 ADHERENCE TO RESPIRATORY MEDICATIONS IN VA PATIENTS WITH CHRONIC LUNG DISEASE
|
Lee, TA
|
|
2005
|
8 |
3 |
p. 327-328
2 p.
|
artikel
|
| 519 |
PRS2 AN ASSESSMENT OF DIAGNOSIS AND TREATMENT OF COPD IN PRIMARY CARE VIA AN ELECTRONIC MEDICAL RECORD DATABASE
|
Joish, V
|
|
2005
|
8 |
3 |
p. 325-
1 p.
|
artikel
|
| 520 |
PRS11 COMMUNITY PHARMACISTS AND TUBERCULOSIS IN THE DOTS ERA- A CROSS-SECTIONAL STUDY OF LAGOS STATE OF NIGERIA
|
Okolo, CO
|
|
2005
|
8 |
3 |
p. 328-
1 p.
|
artikel
|
| 521 |
PRS6 COMPARISON OF RESOURCE USE AND DIRECT COSTS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH AND WITHOUT COMORBID DEPRESSION IN 2001
|
Viswanathan, H
|
|
2005
|
8 |
3 |
p. 326-327
2 p.
|
artikel
|
| 522 |
PRS8 COST-EFFECTIVENESS ANALYSIS OF TIOTROPIUM FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS IN JAPAN
|
Nishimura, S
|
|
2005
|
8 |
3 |
p. 327-
1 p.
|
artikel
|
| 523 |
PRS4 ESTIMATING THE NUMBER OF CASES OF DIAGNOSED CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): USE OF MEDICAL CLAIMS DATA VERSUS ALTERNATIVE METHODOLOGIES
|
Miller, JD
|
|
2005
|
8 |
3 |
p. 326-
1 p.
|
artikel
|
| 524 |
PRS5 EVALUATION OF THE ASSOCIATION BETWEEN SEVERITY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) WITH HEALTH-RELATED UTILITY (EQ5DINDEX) AND HEALTH CARE RESOURCE USE
|
Currie, CJ
|
|
2005
|
8 |
3 |
p. 326-
1 p.
|
artikel
|
| 525 |
PRS13 HEALTH CARE EXPENDITURE AND UTILIZATION FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
|
Nurmagambetov, T
|
|
2005
|
8 |
3 |
p. 329-
1 p.
|
artikel
|
| 526 |
PRS7 PHARMACOECONOMIC ANALYSIS OF TIOTROPIUM THERAPY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASES IN HONG KONG ¡V A PRELIMINARY REPORT
|
Lee, KK
|
|
2005
|
8 |
3 |
p. 327-
1 p.
|
artikel
|
| 527 |
PRS15 PREDICTING EXACERBATION EVENTS IN COPD USING ADMINISTRATIVE DATA
|
Nelson, LS
|
|
2005
|
8 |
3 |
p. 329-
1 p.
|
artikel
|
| 528 |
PRS10 PREDICTORS OF DRUG PERSISTENCY FOR ASTHMA AND COPD PATIENTS
|
Lipskiy, N
|
|
2005
|
8 |
3 |
p. 328-
1 p.
|
artikel
|
| 529 |
PRS1 PULMONOLOGISTS' PERCEPTIONS OF ANEMIA IN COPD: A SURVEY
|
Zilberberg, M
|
|
2005
|
8 |
3 |
p. 325-
1 p.
|
artikel
|
| 530 |
PRS12 RACIAL DISPARITIES IN PREDICTORS OF HEART FAILURE IN MEDICAID PATIENTS WITH COPD
|
Shaya, FT
|
|
2005
|
8 |
3 |
p. 328-329
2 p.
|
artikel
|
| 531 |
PRS14 RISK-BENEFIT ASSESSMENT OF TELITHROMYCIN FOR THE TREATMENT OF CAP USING QUALITY-ADJUSTED DAYS (QAD) LOST
|
McGarry, LJ
|
|
2005
|
8 |
3 |
p. 329-
1 p.
|
artikel
|
| 532 |
PSK1 COST-EFFECTIVENESS ANALYSIS OF AMEVIVE TM (ALEFACEPT) IN THE TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS
|
Iskedjian, M
|
|
2005
|
8 |
3 |
p. 330-
1 p.
|
artikel
|
| 533 |
PSK5 COST-UTILITY ANALYSIS OF AMEVIVE TM (ALEFACEPT) IN THE TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS
|
Iskedjian, M
|
|
2005
|
8 |
3 |
p. 331-
1 p.
|
artikel
|
| 534 |
PSK3 FACTORS ASSOCIATED WITH MEDICATION USE AFFECTING HEALTH CARE COSTS IN PATIENTS WITH PSORIASIS IN THE UNITED STATES
|
Kulkarni, AS
|
|
2005
|
8 |
3 |
p. 330-331
2 p.
|
artikel
|
| 535 |
PSK8 IMPACT OF ATOPIC DERMATITIS ON THE QUALITY-OF-LIFE OF PARENTS OF CHILDREN WITH ATOPIC DERMATITIS
|
Arnold, RJG
|
|
2005
|
8 |
3 |
p. 332-
1 p.
|
artikel
|
| 536 |
PSK6 INTERPRETING SCORES ON THE QUALITY OF LIFE INDEX FOR ATOPIC DERMATITIS (QOLIAD)
|
Meads, DM
|
|
2005
|
8 |
3 |
p. 331-332
2 p.
|
artikel
|
| 537 |
PSK2 NUMBERS-NEEDED-TO-TREAT AND ASSOCIATED COSTS OF CARE FOR TREATMENT OF MODERATE-TO-SEVERE PSORIASIS
|
Hankin, C
|
|
2005
|
8 |
3 |
p. 330-
1 p.
|
artikel
|
| 538 |
PSK9 PREVALENCE OF CHRONIC HAND DERMATITIS AND ITS IMPACT ON PATIENT–REPORTED OUTCOMES IN A MANAGED CARE POPULATION
|
Fowler, JF
|
|
2005
|
8 |
3 |
p. 332-333
2 p.
|
artikel
|
| 539 |
PSK4 THE LIFETIME COST OF TREATING SEVERE PSORIASIS WITH HOME UVB THERAPY
|
Yelverton, CB
|
|
2005
|
8 |
3 |
p. 331-
1 p.
|
artikel
|
| 540 |
PSK10 THE NEGATIVE IMPACT OF PSORIASIS ON WORK PRODUCTIVITY
|
Pearce, DJ
|
|
2005
|
8 |
3 |
p. 333-
1 p.
|
artikel
|
| 541 |
PSK7 USING DUAN'S SMEARING ESTIMATOR TO MEASURE COST OF CHRONIC HAND DERMATITIS (CHHD) IN A MASSACHUSETTS HEALTH MAINTENANCE ORGANIZATION (HMO)
|
Ghosh, A
|
|
2005
|
8 |
3 |
p. 332-
1 p.
|
artikel
|
| 542 |
PSM2 CONFIRMATORY FACTOR ANALYSIS AND RELIABILITY OF THE “SMOKING EFFECTS INVENTORY”
|
Cappelleri, JC
|
|
2005
|
8 |
3 |
p. 333-334
2 p.
|
artikel
|
| 543 |
PSM3 CONFIRMATORY VALIDATION OF THE BRIEF QUESTIONNAIRE OF SMOKING URGES
|
Cappelleri, JC
|
|
2005
|
8 |
3 |
p. 334-
1 p.
|
artikel
|
| 544 |
PSM1 DEVELOPING MARKOV-MODEL INCLUDING TOBACCO-ASSOCIATED DISEASES TO EVALUATE SMOKING CESSATION THERAPY IN JAPAN
|
Igarashi, A
|
|
2005
|
8 |
3 |
p. 333-
1 p.
|
artikel
|
| 545 |
PSR8 BUILDING A LINK BETWEEN DISABILITY AFTER AN ISCHEMIC STROKE AND NEED FOR FOLLOW-UP CARE
|
Hankey, G
|
|
2005
|
8 |
3 |
p. 336-
1 p.
|
artikel
|
| 546 |
PSR5 CONTINUITY OF CARE IN STROKE PATIENTS UNDER REHABILITATION IN MEXICO
|
Constantino-Casas, P
|
|
2005
|
8 |
3 |
p. 335-
1 p.
|
artikel
|
| 547 |
PSR1 COST-EFFECTIVENESS OF CLOPIDOGREL VERSUS ASPIRIN IN THE PREVENTION OF ISCHEMIC EVENTS IN STROKE AND TIA PATIENTS: A FOUR-EUROPEAN COUNTRY ANALYSIS
|
Palmer, AJ
|
|
2005
|
8 |
3 |
p. 334-
1 p.
|
artikel
|
| 548 |
PSR7 DISABILITY MEASURES IN STROKE: SCORE CONVERSION BETWEEN THE BARTHEL INDEX AND THE MOTOR COMPONENT OF FUNCTIONAL INDEPENDENCE MEASURE FOR PRACTITIONER
|
Kwon, S
|
|
2005
|
8 |
3 |
p. 336-
1 p.
|
artikel
|
| 549 |
PSR2 EVALUATING THE POTENTIAL COST-EFFECTIVENESS OF FUTURE ANTICOAGULANT DRUGS VS. WARFARIN IN THE PREVENTION OF STROKE AND MAJOR BLEEDS IN ATRIAL FIBRILLATION PATIENTS
|
Arant, T
|
|
2005
|
8 |
3 |
p. 334-
1 p.
|
artikel
|
| 550 |
PSR4 FREQUENCY OF INR TESTING IN MEDICARE BENEFICIARIES AT HIGH RISK FOR STROKE
|
Santry, B
|
|
2005
|
8 |
3 |
p. 335-
1 p.
|
artikel
|
| 551 |
PSR6 STROKE RECURRENCE AND PERSISTENCE ON DRUG THERAPY IN A MEDICAID POPULATION
|
Shaya, FT
|
|
2005
|
8 |
3 |
p. 335-336
2 p.
|
artikel
|
| 552 |
PSR3 THE EVALUATION OF HEALTH RELATED UTILITY (EQ5D INDEX) AND RESOURCE USE IN PATIENTS WITH STROKE COMPLICATED BY UPPER AND LOWER LIMB SPASTICITY
|
Robinson, K
|
|
2005
|
8 |
3 |
p. 334-335
2 p.
|
artikel
|
| 553 |
PST3 COST-UTILITY OF STENTING FOR SYMPTOMATIC INTRACRANIAL ATHEROSCLEROTIC DISEASE
|
Hornberger, J
|
|
2005
|
8 |
3 |
p. 337-
1 p.
|
artikel
|
| 554 |
PST1 ECONOMIC EVALUATION OF SIROLIMUS-ELUTING STENTS IN JAPAN
|
Kobayashi, M
|
|
2005
|
8 |
3 |
p. 336-337
2 p.
|
artikel
|
| 555 |
PST2 INPATIENT RESOURCE UTILIZATION AND COSTS OF PROCEDURES IMPLANTING DRUG-ELUTING STENTS IN COMPLEX CASES:THE ARRIVE REGISTRY
|
Olchanski, N
|
|
2005
|
8 |
3 |
p. 337-
1 p.
|
artikel
|
| 556 |
PSU1 ECONOMIC BURDEN OF ILLNESS ASSOCIATED WITH CODED POSTOPERATIVE ILEUS AFTER OPEN LAPAROTOMIES
|
Wang, PF
|
|
2005
|
8 |
3 |
p. 338-
1 p.
|
artikel
|
| 557 |
PSU2 ELECTIVE SURGERIES IN THE US: RISK FACTORS, COST, AND OUTCOMES
|
Saunders, WB
|
|
2005
|
8 |
3 |
p. 338-
1 p.
|
artikel
|
| 558 |
PUK4 A COMPARISON OF TOTAL DIRECT MEDICAL COSTS AMONG PATIENTS RECEIVING AGENTS USED IN THE PHARMACOLOGIC MANAGEMENT OF OVERACTIVE BLADDER
|
Harris, HM
|
|
2005
|
8 |
3 |
p. 414-
1 p.
|
artikel
|
| 559 |
PUK11 ADHERENCE TO EXTENDED RELEASE TOLTERODINE VERSUS IMMEDIATE- AND EXTENDED-RELEASE OXYBUTYNIN AMONG COMMERCIALLY-INSURED PATIENTS WITH OVERACTIVE BLADDER
|
Ollendorf, DA
|
|
2005
|
8 |
3 |
p. 416-
1 p.
|
artikel
|
| 560 |
PUK12 ADHERENCE WITH MEDICATIONS USED TO TREAT OVERACTIVE BLADDER IN A MANAGED CARE POPULATION.
|
D'Angio, RG
|
|
2005
|
8 |
3 |
p. 416-
1 p.
|
artikel
|
| 561 |
PUK3 AN ECONOMIC MODEL OF OVERACTIVE BLADDER TREATMENT PERSISTENCE:TOLTERODINE ER COMPARED TO OXYBUTYNIN ER
|
Subedi, P
|
|
2005
|
8 |
3 |
p. 413-414
2 p.
|
artikel
|
| 562 |
PUK6 A PHARMACOECONOMIC EVALUATION OF OXYBUTYNIN AND TOLTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER
|
Ko, Y
|
|
2005
|
8 |
3 |
p. 414-415
2 p.
|
artikel
|
| 563 |
PUK21 DEGREE OF SYMPTOM BOTHER IN URINARY INCONTINENCE
|
Del, Aguila MA
|
|
2005
|
8 |
3 |
p. 419-
1 p.
|
artikel
|
| 564 |
PUK16 DOSING PATTERNS OF ERYTHROPOIETIC AGENTS IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE
|
Duh, MS
|
|
2005
|
8 |
3 |
p. 418-
1 p.
|
artikel
|
| 565 |
PUK5 ECONOMIC EVALUATION OF EVEROLIMUS WITH REDUCED- DOSE CYCLOSPORINE IN DE NOVO RENAL TRANSPLANT RECIPIENTS: AN INTERNATIONAL PERSPECTIVE
|
Ethgen, O
|
|
2005
|
8 |
3 |
p. 414-
1 p.
|
artikel
|
| 566 |
PUK10 EPOETIN ALFA AND DARBEPOETIN ALFA DOSING TRENDS IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS
|
Mody, S
|
|
2005
|
8 |
3 |
p. 416-
1 p.
|
artikel
|
| 567 |
PUK19 ESTABLISHING THE CONTENT VALIDITY OF THE URINARY SENSATION SCALE (USS)
|
Brewster, JL
|
|
2005
|
8 |
3 |
p. 418-419
2 p.
|
artikel
|
| 568 |
PUK7 ESTIMATING THE COST SAVINGS DUE TO THE EFFECT OF KREMEZIN IN DELAYING THE ONSET OF RECEIVING DIALYSIS TREATMENTS AMONG PATIENTS WITH CHRONIC RENAL FAILURE
|
Kang, HY
|
|
2005
|
8 |
3 |
p. 415-
1 p.
|
artikel
|
| 569 |
PUK18 EVALUATION OF THE RELIABILITY AND VALIDITY OF THE INCONTINENCE QUALITY OF LIFE QUESTIONNAIRE (I-QOL) IN PATIENTS WITH DETRUSOR HYPERREFLEXIA
|
Barron, R
|
|
2005
|
8 |
3 |
p. 418-
1 p.
|
artikel
|
| 570 |
PUK14 FACTORS INFLUENCING THE ROUTE OF ADMINISTRATION FOR EPOETIN TREATMENT AMONG U.S. HEMODIALYSIS PATIENTS
|
Thamer, M
|
|
2005
|
8 |
3 |
p. 417-
1 p.
|
artikel
|
| 571 |
PUK15 IMPACTS OF IMPLEMENTING CASE PAYMENT SYSEM TO HEMODIALYSIS OF MEDICAL AID PATIENTS ON DIALYSIS FREQUENCIES AND EXPENDITURE IN KOREA
|
Kang, HY
|
|
2005
|
8 |
3 |
p. 417-
1 p.
|
artikel
|
| 572 |
PUK9 INTERSTITIAL CYSTITIS COSTS, TREATMENT AND COMORBIDITIES IN AN EMPLOYED POPULATION
|
Wu, EQ
|
|
2005
|
8 |
3 |
p. 415-416
2 p.
|
artikel
|
| 573 |
PUK20 PATIENT SELECTION CRITERIA IMPACTS OUTCOMES IN A RETROSPECTIVE OAB STUDY
|
Del, Aguila MA
|
|
2005
|
8 |
3 |
p. 419-
1 p.
|
artikel
|
| 574 |
PUK13 PREDICTORS OF MEDICATION ADHERENCE AND ASSOCIATED HEALTH CARE COSTS IN AN OLDER POPULATION WITH DETRUSOR OVERACTIVITY: A LONGITUDINAL COHORT STUDY
|
Balkrishnan, R
|
|
2005
|
8 |
3 |
p. 417-
1 p.
|
artikel
|
| 575 |
PUK17 PREVALENCE, DEMOGRAPHICS, AND PHARMACOLOGICAL TREATMENT PATTERNS OF OVERACTIVE BLADDER IN A MANAGED CARE POPULATION
|
Daniel, G
|
|
2005
|
8 |
3 |
p. 418-
1 p.
|
artikel
|
| 576 |
PUK1 SELECTED OUTCOMES IN PATIENTS WITH OVERACTIVE BLADDER COMPARED TO NON-OVERACTIVE BLADDER CONTROLS
|
Daniel, G
|
|
2005
|
8 |
3 |
p. 413-
1 p.
|
artikel
|
| 577 |
PUK2 THE COST-EFFECTIVENESS OF SUBSTITUTING DARBAPOETIN FOR EPOETIN:WHEN ECONOMIC MODELLING DOES NOT PREDICT REAL LIFE RESULTS
|
Basskin, LE
|
|
2005
|
8 |
3 |
p. 413-
1 p.
|
artikel
|
| 578 |
PUK8 THE DIRECT COSTS OF STRESS URINARY INCONTINENCE TREATMENT AMONG WOMEN IN A MEDICAID POPULATION
|
Kinchen, K
|
|
2005
|
8 |
3 |
p. 415-
1 p.
|
artikel
|
| 579 |
QLI IS RELIEF WORTH THE RISK? RISK-BENEFIT PREFERENCES FOR TREATMENTS FORVASOMOTOR SYMPTOMS
|
Johnson, FR
|
|
2005
|
8 |
3 |
p. 244-245
2 p.
|
artikel
|
| 580 |
QL2 NEW WEIGHTS FOR OLD: A SCALE OF VALUES FOR EQ-5D HEALTH STATES
|
Kind, P
|
|
2005
|
8 |
3 |
p. 245-
1 p.
|
artikel
|
| 581 |
QL4 THE CONTENT VALIDITY OF CLINICIAN DERIVED PATIENT REPORTED OUTCOMES (PRO) MEASURES: THE ROLAND MORRIS DISABILITY QUESTIONNAIRE
|
Horowicz-Mehler, N
|
|
2005
|
8 |
3 |
p. 245-246
2 p.
|
artikel
|
| 582 |
RS2 ASSESSING HEALTH-RELATED QUALITY OF LIFE USING THE SF-I2V2 FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
|
Martinez, FJ
|
|
2005
|
8 |
3 |
p. 246-
1 p.
|
artikel
|
| 583 |
RS3 ESTIMATING THE COST-EFFECTIVENESS OF FLUTICASONE PROPIONATE FORTREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE
|
Briggs, A
|
|
2005
|
8 |
3 |
p. 246-247
2 p.
|
artikel
|
| 584 |
RSI QUALITY OF LIFE IN ASTHMA PATIENTS IS AFFECTED BY HOME TELEMANAGEMENT
|
Joshi, A
|
|
2005
|
8 |
3 |
p. 246-
1 p.
|
artikel
|
| 585 |
RS4 PRESCRIBING PATTERNS IN AMBULATORY CARE CENTERS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
|
Mahajan, S
|
|
2005
|
8 |
3 |
p. 247-
1 p.
|
artikel
|
| 586 |
The Economic Value of Childhood Varicella Vaccination in France and Germany
|
Coudeville, Laurent
|
|
2005
|
8 |
3 |
p. 209-222
14 p.
|
artikel
|
Tijdschrift beschrijving